

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the Query Builder analysis.

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview

Query Builder Report: This report details the results of an analysis generated by the Sentinel Query Builder application. Query Builder enables FDA to visualize, draft, and create standardized medical product utilization queries examining dispensing patterns and cohort characteristics using a set of pre-defined parameters. This is a Type 5 (Medical Product Utilization) analysis as described in the Query Request Package (QRP) documentation.

Data Source: We executed this request on IBM® MarketScan® Commercial Claims and Encounters Database and Medicare Supplemental Database, which included 142 million members, on September 23, 2020. The study period included data from January 1, 2013 to March 31, 2019. Please see Appendix A for data availability dates.

Request Description: In this request, we described utilization patterns of mixed amphetamine salts immediate-release tablets by manufacturer. Please see Appendix B for the specifications of parameters used in this request.

We defined the mixed amphetamine salts immediate-release tablet exposures using National Drug Codes (NDCs). Please see Appendix C for a list of NDCs used to define the products evaluated in this request.

We required evidence of a narcolepsy/attention deficit hyperactivity disorder (ADHD) diagnosis in the 183 days prior to the index dispensing. We defined this inclusion requirement using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes. Please see Appendix D for the specific diagnosis codes used.

We required patients to be enrolled in health plans with medical and drug coverage in the 183 days prior to their index date in order to be included in the cohort. Gaps in treatment episodes were allowed and varied by cohort: up to 14 days, up to 7 days, or no gap in coverage. Treatment episode extensions were also allowed; for all cohorts, the episode extension length was equal to the gap length.

This is Report 2 of 2. Report 1 details utilization of mixed amphetamine salts immediate-release tablets for an additional ten cohorts, by product manufacturer.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 9.1.0.

Limitations: Algorithms used to define exposures and inclusion and exclusion criteria are imperfect; thus it is possible that there may be misclassification. Therefore, data should be interpreted with these limitations in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel Query Builder, please refer to the documentation (<https://dev.sentinelssystem.org/projects/QB/repos/querybuilder/browse>).

Table of contents	
Table 1a	Baseline table (SpecGx Mixed Amphetamine Salt, 7 Day Gap)
Table 1b	Baseline table (SpecGx Mixed Amphetamine Salt, 14 Day Gap)
Table 1c	Baseline table (Aurolife Mixed Amphetamine Salt, 0 Day Gap)
Table 1d	Baseline table (Aurolife Mixed Amphetamine Salt, 7 Day Gap)
Table 1e	Baseline table (Aurolife Mixed Amphetamine Salt, 14 Day Gap)
Table 1f	Baseline table (Any Mixed Amphetamine Salt, 0 Day Gap)
Table 1g	Baseline table (Any Mixed Amphetamine Salt, 7 Day Gap)
Table 1h	Baseline table (Any Mixed Amphetamine Salt, 14 Day Gap)
Table 1i	Baseline table (Any Mixed Amphetamine Salt, 30 Day Gap)
Table 1j	Baseline table (Any Mixed Amphetamine Salt, 45 Day Gap)
Table 2a	Descriptive statistics of cumulative exposure duration, all episodes, in days
Table 2b	Descriptive statistics of cumulative exposure duration, all episodes, in days, by sex
Table 2c	Descriptive statistics of cumulative exposure duration, all episodes, in days, by age group (years)
Table 3a	Descriptive statistics of first exposure episode duration, in days
Table 3b	Descriptive statistics of first exposure episode duration, in days, by sex
Table 3c	Descriptive statistics of first exposure episode duration, in days, by age group (years)
Table 4a	Descriptive statistics of all episode durations, in days
Table 4b	Descriptive statistics of all episode durations, in days, by sex
Table 4c	Descriptive statistics of all episode durations, in days, by age group (years)
Table 5a	Descriptive statistics of days supplied per dispensing
Table 5b	Descriptive statistics of days supplied per dispensing, by sex
Table 5c	Descriptive statistics of days supplied per dispensing, by age group (years)
Table 6a	Descriptive statistics of the length of all gaps between treatment episodes, in days
Table 6b	Descriptive statistics of the length of all gaps between treatment episodes, in days, by sex
Table 6c	Descriptive statistics of the length of all gaps between treatment episodes, in days, by age group (years)
Table 7	Counts of reason for censoring, all episodes and first episode
Table 8	Cohort Attrition table
Appendix A	Dates of Available Data for Each Data Partner (DP) up to Request End Date (03/31/2019) as of Query Distribution Date
Appendix B	Specifications Used to Define Parameters in this Query
Appendix C	List of National Drug Codes (NDCs) and Generic Names of Medical Products Used to Define Index Exposures in this Request
Appendix D	List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Inclusion Criteria in this Request

Table 1a: Baseline table (SpecGx Mixed Amphetamine Salt, 7 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	37,344	
Demographics		
Mean Age (years)	34.8	13.0
Age (years): 00-01	-	-
Age (years): 02-04	6	0.0%
Age (years): 05-09	498	1.3%
Age (years): 10-14	1,311	3.5%
Age (years): 15-18	1,698	4.5%
Age (years): 19-21	2,543	6.8%
Age (years): 22-44	22,684	60.7%
Age (years): 45-64	8,401	22.5%
Age (years): 65-74	187	0.5%
Age (years): 75+	16	0.0%
Sex (Female)	19,784	53.0%
Sex (Male)	17,560	47.0%
Year (2013)	2	0.0%
Year (2014)	9,043	24.2%
Year (2015)	2,484	6.7%
Year (2016)	2,011	5.4%
Year (2017)	6,618	17.7%
Year (2018)	12,590	33.7%
Year (2019)	4,596	12.3%
Recorded history of:		
Prior combined comorbidity score ³	0.3	0.8
Acquired Hypothyroidism	2,113	5.7%
Acute Myocardial Infarction	17	0.0%
Alzheimer's Disease	5	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	46	0.1%
Anemia	1,174	3.1%
Asthma	1,782	4.8%
Atrial Fibrillation	70	0.2%
Benign Prostatic Hyperplasia	232	0.6%
Breast Cancer	151	0.4%
Cataracts	295	0.8%
Chronic Kidney Disease	597	1.6%
Chronic Obstructive Pulmonary Disease	698	1.9%
Colorectal Cancer	34	0.1%
Depression	8,919	23.9%
Diabetes	1,229	3.3%
Endometrial Cancer	7	0.0%
Glaucoma	211	0.6%
Heart Failure	65	0.2%
Hip / Pelvic Fracture	23	0.1%
Hyperlipidemia	3,708	9.9%
Hypertension	4,612	12.4%
Ischemic Heart Disease	251	0.7%
Lung Cancer	9	0.0%
Osteoporosis	107	0.3%
Prostate Cancer	44	0.1%
Rheumatoid Arthritis / Osteoarthritis	2,341	6.3%
Stroke / Transient Ischemic Attack	79	0.2%

Table 1a: Baseline table (SpecGx Mixed Amphetamine Salt, 7 Day Gap)

Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	6.6	7.1
Mean number of emergency room encounters (ED)	0.2	0.6
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	0.8	2.4
Mean number of filled prescriptions	14.8	11.8
Mean number of generics	5.0	4.0
Mean number of unique drug classes	4.8	3.6

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 1b: Baseline table (SpecGx Mixed Amphetamine Salt, 14 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	37,127	
Demographics		
Mean Age (years)	34.8	13.0
Age (years): 00-01	-	-
Age (years): 02-04	6	0.0%
Age (years): 05-09	495	1.3%
Age (years): 10-14	1,307	3.5%
Age (years): 15-18	1,691	4.6%
Age (years): 19-21	2,522	6.8%
Age (years): 22-44	22,566	60.8%
Age (years): 45-64	8,340	22.5%
Age (years): 65-74	184	0.5%
Age (years): 75+	16	0.0%
Sex (Female)	19,659	53.0%
Sex (Male)	17,468	47.0%
Year (2013)	2	0.0%
Year (2014)	8,939	24.1%
Year (2015)	2,461	6.6%
Year (2016)	2,000	5.4%
Year (2017)	6,601	17.8%
Year (2018)	12,531	33.8%
Year (2019)	4,593	12.4%
Recorded history of:		
Prior combined comorbidity score ³	0.3	0.8
Acquired Hypothyroidism	2,095	5.6%
Acute Myocardial Infarction	17	0.0%
Alzheimer's Disease	5	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	46	0.1%
Anemia	1,166	3.1%
Asthma	1,777	4.8%
Atrial Fibrillation	70	0.2%
Benign Prostatic Hyperplasia	230	0.6%
Breast Cancer	150	0.4%
Cataracts	292	0.8%
Chronic Kidney Disease	596	1.6%
Chronic Obstructive Pulmonary Disease	695	1.9%
Colorectal Cancer	34	0.1%
Depression	8,873	23.9%
Diabetes	1,222	3.3%
Endometrial Cancer	7	0.0%
Glaucoma	209	0.6%
Heart Failure	65	0.2%
Hip / Pelvic Fracture	23	0.1%
Hyperlipidemia	3,686	9.9%
Hypertension	4,580	12.3%
Ischemic Heart Disease	247	0.7%
Lung Cancer	9	0.0%
Osteoporosis	107	0.3%
Prostate Cancer	42	0.1%
Rheumatoid Arthritis / Osteoarthritis	2,324	6.3%
Stroke / Transient Ischemic Attack	79	0.2%

Table 1b: Baseline table (SpecGx Mixed Amphetamine Salt, 14 Day Gap)

Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	6.6	7.1
Mean number of emergency room encounters (ED)	0.2	0.6
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	0.8	2.4
Mean number of filled prescriptions	14.8	11.8
Mean number of generics	5.0	4.0
Mean number of unique drug classes	4.8	3.6

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 1c: Baseline table (Aurolife Mixed Amphetamine Salt, 0 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	178,453	
Demographics		
Mean Age (years)	32.3	13.2
Age (years): 00-01	2	0.0%
Age (years): 02-04	189	0.1%
Age (years): 05-09	5,618	3.1%
Age (years): 10-14	9,164	5.1%
Age (years): 15-18	10,689	6.0%
Age (years): 19-21	14,662	8.2%
Age (years): 22-44	104,803	58.7%
Age (years): 45-64	32,617	18.3%
Age (years): 65-74	645	0.4%
Age (years): 75+	64	0.0%
Sex (Female)	94,728	53.1%
Sex (Male)	83,725	46.9%
Year (2013)	-	-
Year (2014)	26,985	15.1%
Year (2015)	19,768	11.1%
Year (2016)	24,471	13.7%
Year (2017)	57,642	32.3%
Year (2018)	39,194	22.0%
Year (2019)	10,393	5.8%
Recorded history of:		
Prior combined comorbidity score ³	0.3	0.8
Acquired Hypothyroidism	9,579	5.4%
Acute Myocardial Infarction	74	0.0%
Alzheimer's Disease	24	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	267	0.1%
Anemia	5,373	3.0%
Asthma	9,063	5.1%
Atrial Fibrillation	304	0.2%
Benign Prostatic Hyperplasia	882	0.5%
Breast Cancer	635	0.4%
Cataracts	1,227	0.7%
Chronic Kidney Disease	2,759	1.5%
Chronic Obstructive Pulmonary Disease	2,939	1.6%
Colorectal Cancer	135	0.1%
Depression	41,067	23.0%
Diabetes	4,941	2.8%
Endometrial Cancer	46	0.0%
Glaucoma	1,017	0.6%
Heart Failure	253	0.1%
Hip / Pelvic Fracture	88	0.0%
Hyperlipidemia	15,717	8.8%
Hypertension	18,214	10.2%
Ischemic Heart Disease	1,035	0.6%
Lung Cancer	51	0.0%
Osteoporosis	522	0.3%
Prostate Cancer	145	0.1%
Rheumatoid Arthritis / Osteoarthritis	9,383	5.3%
Stroke / Transient Ischemic Attack	401	0.2%

Characteristic¹	N/Mean	%/Std Dev²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	6.7	7.3
Mean number of emergency room encounters (ED)	0.2	0.6
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	0.8	2.6
Mean number of filled prescriptions	13.5	11.3
Mean number of generics	5.0	4.0
Mean number of unique drug classes	4.8	3.6

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 1d: Baseline table (Aurolife Mixed Amphetamine Salt, 7 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	174,764	
Demographics		
Mean Age (years)	32.2	13.2
Age (years): 00-01	2	0.0%
Age (years): 02-04	187	0.1%
Age (years): 05-09	5,556	3.2%
Age (years): 10-14	9,056	5.2%
Age (years): 15-18	10,593	6.1%
Age (years): 19-21	14,486	8.3%
Age (years): 22-44	102,304	58.5%
Age (years): 45-64	31,895	18.3%
Age (years): 65-74	622	0.4%
Age (years): 75+	63	0.0%
Sex (Female)	92,727	53.1%
Sex (Male)	82,037	46.9%
Year (2013)	-	-
Year (2014)	26,595	15.2%
Year (2015)	19,274	11.0%
Year (2016)	23,828	13.6%
Year (2017)	56,061	32.1%
Year (2018)	38,511	22.0%
Year (2019)	10,495	6.0%
Recorded history of:		
Prior combined comorbidity score ³	0.3	0.8
Acquired Hypothyroidism	9,328	5.3%
Acute Myocardial Infarction	74	0.0%
Alzheimer's Disease	23	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	260	0.1%
Anemia	5,244	3.0%
Asthma	8,919	5.1%
Atrial Fibrillation	300	0.2%
Benign Prostatic Hyperplasia	859	0.5%
Breast Cancer	624	0.4%
Cataracts	1,204	0.7%
Chronic Kidney Disease	2,717	1.6%
Chronic Obstructive Pulmonary Disease	2,879	1.6%
Colorectal Cancer	131	0.1%
Depression	40,199	23.0%
Diabetes	4,820	2.8%
Endometrial Cancer	46	0.0%
Glaucoma	1,010	0.6%
Heart Failure	251	0.1%
Hip / Pelvic Fracture	90	0.1%
Hyperlipidemia	15,305	8.8%
Hypertension	17,777	10.2%
Ischemic Heart Disease	1,019	0.6%
Lung Cancer	49	0.0%
Osteoporosis	511	0.3%
Prostate Cancer	141	0.1%
Rheumatoid Arthritis / Osteoarthritis	9,190	5.3%
Stroke / Transient Ischemic Attack	391	0.2%

Table 1d: Baseline table (Aurolife Mixed Amphetamine Salt, 7 Day Gap)		
Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	6.7	7.3
Mean number of emergency room encounters (ED)	0.2	0.6
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	0.8	2.6
Mean number of filled prescriptions	13.5	11.2
Mean number of generics	5.0	4.0
Mean number of unique drug classes	4.8	3.6

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 1e: Baseline table (Aurolife Mixed Amphetamine Salt, 14 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	172,492	
Demographics		
Mean Age (years)	32.2	13.2
Age (years): 00-01	2	0.0%
Age (years): 02-04	185	0.1%
Age (years): 05-09	5,511	3.2%
Age (years): 10-14	8,986	5.2%
Age (years): 15-18	10,518	6.1%
Age (years): 19-21	14,358	8.3%
Age (years): 22-44	100,834	58.5%
Age (years): 45-64	31,421	18.2%
Age (years): 65-74	615	0.4%
Age (years): 75+	62	0.0%
Sex (Female)	91,464	53.0%
Sex (Male)	81,028	47.0%
Year (2013)	-	-
Year (2014)	26,380	15.3%
Year (2015)	18,924	11.0%
Year (2016)	23,436	13.6%
Year (2017)	55,146	32.0%
Year (2018)	38,075	22.1%
Year (2019)	10,531	6.1%
Recorded history of:		
Prior combined comorbidity score ³	0.3	0.8
Acquired Hypothyroidism	9,193	5.3%
Acute Myocardial Infarction	74	0.0%
Alzheimer's Disease	22	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	258	0.1%
Anemia	5,173	3.0%
Asthma	8,789	5.1%
Atrial Fibrillation	292	0.2%
Benign Prostatic Hyperplasia	846	0.5%
Breast Cancer	611	0.4%
Cataracts	1,190	0.7%
Chronic Kidney Disease	2,684	1.6%
Chronic Obstructive Pulmonary Disease	2,850	1.7%
Colorectal Cancer	131	0.1%
Depression	39,617	23.0%
Diabetes	4,753	2.8%
Endometrial Cancer	47	0.0%
Glaucoma	992	0.6%
Heart Failure	250	0.1%
Hip / Pelvic Fracture	89	0.1%
Hyperlipidemia	15,084	8.7%
Hypertension	17,504	10.1%
Ischemic Heart Disease	1,009	0.6%
Lung Cancer	50	0.0%
Osteoporosis	502	0.3%
Prostate Cancer	140	0.1%
Rheumatoid Arthritis / Osteoarthritis	9,057	5.3%
Stroke / Transient Ischemic Attack	381	0.2%

Table 1e: Baseline table (Aurolife Mixed Amphetamine Salt, 14 Day Gap)

Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	6.7	7.3
Mean number of emergency room encounters (ED)	0.2	0.6
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	0.8	2.6
Mean number of filled prescriptions	13.5	11.2
Mean number of generics	5.0	4.0
Mean number of unique drug classes	4.8	3.6

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 1f: Baseline table (Any Mixed Amphetamine Salt, 0 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	413,490	
Demographics		
Mean Age (years)	29.1	13.6
Age (years): 00-01	6	0.0%
Age (years): 02-04	984	0.2%
Age (years): 05-09	23,526	5.7%
Age (years): 10-14	33,973	8.2%
Age (years): 15-18	39,407	9.5%
Age (years): 19-21	44,524	10.8%
Age (years): 22-44	209,174	50.6%
Age (years): 45-64	60,424	14.6%
Age (years): 65-74	1,317	0.3%
Age (years): 75+	155	0.0%
Sex (Female)	209,346	50.6%
Sex (Male)	204,144	49.4%
Year (2013)	74,226	18.0%
Year (2014)	75,329	18.2%
Year (2015)	63,598	15.4%
Year (2016)	68,072	16.5%
Year (2017)	63,367	15.3%
Year (2018)	54,487	13.2%
Year (2019)	14,411	3.5%
Recorded history of:		
Prior combined comorbidity score ³	0.3	0.7
Acquired Hypothyroidism	19,097	4.6%
Acute Myocardial Infarction	118	0.0%
Alzheimer's Disease	47	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	554	0.1%
Anemia	11,086	2.7%
Asthma	22,034	5.3%
Atrial Fibrillation	556	0.1%
Benign Prostatic Hyperplasia	1,711	0.4%
Breast Cancer	1,160	0.3%
Cataracts	2,274	0.5%
Chronic Kidney Disease	4,608	1.1%
Chronic Obstructive Pulmonary Disease	6,436	1.6%
Colorectal Cancer	224	0.1%
Depression	87,619	21.2%
Diabetes	9,816	2.4%
Endometrial Cancer	82	0.0%
Glaucoma	2,224	0.5%
Heart Failure	481	0.1%
Hip / Pelvic Fracture	194	0.0%
Hyperlipidemia	30,449	7.4%
Hypertension	31,836	7.7%
Ischemic Heart Disease	1,978	0.5%
Lung Cancer	69	0.0%
Osteoporosis	1,018	0.2%
Prostate Cancer	282	0.1%
Rheumatoid Arthritis / Osteoarthritis	16,383	4.0%
Stroke / Transient Ischemic Attack	796	0.2%

Table 1f: Baseline table (Any Mixed Amphetamine Salt, 0 Day Gap)

Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	6.6	7.3
Mean number of emergency room encounters (ED)	0.2	0.6
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	0.8	2.6
Mean number of filled prescriptions	10.4	10.0
Mean number of generics	4.7	3.8
Mean number of unique drug classes	4.5	3.4

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 1g: Baseline table (Any Mixed Amphetamine Salt, 7 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	403,431	
Demographics		
Mean Age (years)	29.0	13.6
Age (years): 00-01	5	0.0%
Age (years): 02-04	979	0.2%
Age (years): 05-09	23,233	5.8%
Age (years): 10-14	33,492	8.3%
Age (years): 15-18	38,918	9.6%
Age (years): 19-21	43,772	10.8%
Age (years): 22-44	203,064	50.3%
Age (years): 45-64	58,540	14.5%
Age (years): 65-74	1,276	0.3%
Age (years): 75+	152	0.0%
Sex (Female)	204,023	50.6%
Sex (Male)	199,408	49.4%
Year (2013)	71,880	17.8%
Year (2014)	73,537	18.2%
Year (2015)	62,025	15.4%
Year (2016)	66,664	16.5%
Year (2017)	61,810	15.3%
Year (2018)	53,187	13.2%
Year (2019)	14,328	3.6%
Recorded history of:		
Prior combined comorbidity score ³	0.3	0.7
Acquired Hypothyroidism	18,555	4.6%
Acute Myocardial Infarction	113	0.0%
Alzheimer's Disease	49	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	549	0.1%
Anemia	10,797	2.7%
Asthma	21,487	5.3%
Atrial Fibrillation	543	0.1%
Benign Prostatic Hyperplasia	1,662	0.4%
Breast Cancer	1,129	0.3%
Cataracts	2,226	0.6%
Chronic Kidney Disease	4,511	1.1%
Chronic Obstructive Pulmonary Disease	6,229	1.5%
Colorectal Cancer	218	0.1%
Depression	85,461	21.2%
Diabetes	9,508	2.4%
Endometrial Cancer	80	0.0%
Glaucoma	2,184	0.5%
Heart Failure	474	0.1%
Hip / Pelvic Fracture	185	0.0%
Hyperlipidemia	29,519	7.3%
Hypertension	30,807	7.6%
Ischemic Heart Disease	1,920	0.5%
Lung Cancer	66	0.0%
Osteoporosis	1,001	0.2%
Prostate Cancer	274	0.1%
Rheumatoid Arthritis / Osteoarthritis	15,912	3.9%
Stroke / Transient Ischemic Attack	771	0.2%

Table 1g: Baseline table (Any Mixed Amphetamine Salt, 7 Day Gap)

Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	6.6	7.3
Mean number of emergency room encounters (ED)	0.2	0.6
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	0.8	2.6
Mean number of filled prescriptions	10.3	10.0
Mean number of generics	4.7	3.8
Mean number of unique drug classes	4.5	3.4

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 1h: Baseline table (Any Mixed Amphetamine Salt, 14 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	395,371	
Demographics		
Mean Age (years)	29.0	13.6
Age (years): 00-01	5	0.0%
Age (years): 02-04	976	0.2%
Age (years): 05-09	23,009	5.8%
Age (years): 10-14	33,081	8.4%
Age (years): 15-18	38,479	9.7%
Age (years): 19-21	43,112	10.9%
Age (years): 22-44	198,277	50.1%
Age (years): 45-64	57,038	14.4%
Age (years): 65-74	1,247	0.3%
Age (years): 75+	147	0.0%
Sex (Female)	199,658	50.5%
Sex (Male)	195,713	49.5%
Year (2013)	69,821	17.7%
Year (2014)	72,053	18.2%
Year (2015)	60,851	15.4%
Year (2016)	65,587	16.6%
Year (2017)	60,689	15.3%
Year (2018)	52,133	13.2%
Year (2019)	14,237	3.6%
Recorded history of:		
Prior combined comorbidity score ³	0.3	0.7
Acquired Hypothyroidism	18,110	4.6%
Acute Myocardial Infarction	111	0.0%
Alzheimer's Disease	48	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	545	0.1%
Anemia	10,562	2.7%
Asthma	21,072	5.3%
Atrial Fibrillation	523	0.1%
Benign Prostatic Hyperplasia	1,632	0.4%
Breast Cancer	1,101	0.3%
Cataracts	2,181	0.6%
Chronic Kidney Disease	4,421	1.1%
Chronic Obstructive Pulmonary Disease	6,079	1.5%
Colorectal Cancer	214	0.1%
Depression	83,856	21.2%
Diabetes	9,276	2.3%
Endometrial Cancer	78	0.0%
Glaucoma	2,132	0.5%
Heart Failure	463	0.1%
Hip / Pelvic Fracture	179	0.0%
Hyperlipidemia	28,732	7.3%
Hypertension	30,053	7.6%
Ischemic Heart Disease	1,874	0.5%
Lung Cancer	64	0.0%
Osteoporosis	971	0.2%
Prostate Cancer	269	0.1%
Rheumatoid Arthritis / Osteoarthritis	15,546	3.9%
Stroke / Transient Ischemic Attack	750	0.2%

Table 1h: Baseline table (Any Mixed Amphetamine Salt, 14 Day Gap)		
Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	6.7	7.3
Mean number of emergency room encounters (ED)	0.2	0.6
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	0.8	2.6
Mean number of filled prescriptions	10.2	10.0
Mean number of generics	4.7	3.8
Mean number of unique drug classes	4.5	3.4

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 1i: Baseline table (Any Mixed Amphetamine Salt, 30 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	379,334	
Demographics		
Mean Age (years)	28.8	13.6
Age (years): 00-01	5	0.0%
Age (years): 02-04	970	0.3%
Age (years): 05-09	22,571	6.0%
Age (years): 10-14	32,242	8.5%
Age (years): 15-18	37,535	9.9%
Age (years): 19-21	41,858	11.0%
Age (years): 22-44	188,843	49.8%
Age (years): 45-64	54,000	14.2%
Age (years): 65-74	1,170	0.3%
Age (years): 75+	140	0.0%
Sex (Female)	190,880	50.3%
Sex (Male)	188,454	49.7%
Year (2013)	65,675	17.3%
Year (2014)	69,065	18.2%
Year (2015)	58,447	15.4%
Year (2016)	63,505	16.7%
Year (2017)	58,419	15.4%
Year (2018)	50,269	13.3%
Year (2019)	13,954	3.7%
Recorded history of:		
Prior combined comorbidity score ³	0.3	0.7
Acquired Hypothyroidism	17,173	4.5%
Acute Myocardial Infarction	103	0.0%
Alzheimer's Disease	46	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	529	0.1%
Anemia	10,033	2.6%
Asthma	20,292	5.3%
Atrial Fibrillation	506	0.1%
Benign Prostatic Hyperplasia	1,557	0.4%
Breast Cancer	1,036	0.3%
Cataracts	2,074	0.5%
Chronic Kidney Disease	4,257	1.1%
Chronic Obstructive Pulmonary Disease	5,804	1.5%
Colorectal Cancer	200	0.1%
Depression	80,578	21.2%
Diabetes	8,802	2.3%
Endometrial Cancer	76	0.0%
Glaucoma	2,034	0.5%
Heart Failure	443	0.1%
Hip / Pelvic Fracture	168	0.0%
Hyperlipidemia	27,278	7.2%
Hypertension	28,509	7.5%
Ischemic Heart Disease	1,787	0.5%
Lung Cancer	61	0.0%
Osteoporosis	916	0.2%
Prostate Cancer	256	0.1%
Rheumatoid Arthritis / Osteoarthritis	14,788	3.9%
Stroke / Transient Ischemic Attack	717	0.2%

Table 1i: Baseline table (Any Mixed Amphetamine Salt, 30 Day Gap)

Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	6.7	7.3
Mean number of emergency room encounters (ED)	0.2	0.6
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	0.8	2.6
Mean number of filled prescriptions	10.1	9.9
Mean number of generics	4.7	3.8
Mean number of unique drug classes	4.5	3.4

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 1j: Baseline table (Any Mixed Amphetamine Salt, 45 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	366,484	
Demographics		
Mean Age (years)	28.7	13.6
Age (years): 00-01	5	0.0%
Age (years): 02-04	968	0.3%
Age (years): 05-09	22,187	6.1%
Age (years): 10-14	31,465	8.6%
Age (years): 15-18	36,663	10.0%
Age (years): 19-21	40,689	11.1%
Age (years): 22-44	181,660	49.6%
Age (years): 45-64	51,588	14.1%
Age (years): 65-74	1,127	0.3%
Age (years): 75+	132	0.0%
Sex (Female)	183,932	50.2%
Sex (Male)	182,552	49.8%
Year (2013)	62,331	17.0%
Year (2014)	66,694	18.2%
Year (2015)	56,551	15.4%
Year (2016)	61,820	16.9%
Year (2017)	56,725	15.5%
Year (2018)	48,762	13.3%
Year (2019)	13,601	3.7%
Recorded history of:		
Prior combined comorbidity score ³	0.3	0.7
Acquired Hypothyroidism	16,471	4.5%
Acute Myocardial Infarction	101	0.0%
Alzheimer's Disease	43	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	515	0.1%
Anemia	9,679	2.6%
Asthma	19,597	5.3%
Atrial Fibrillation	473	0.1%
Benign Prostatic Hyperplasia	1,481	0.4%
Breast Cancer	995	0.3%
Cataracts	1,992	0.5%
Chronic Kidney Disease	4,117	1.1%
Chronic Obstructive Pulmonary Disease	5,612	1.5%
Colorectal Cancer	188	0.1%
Depression	77,930	21.3%
Diabetes	8,466	2.3%
Endometrial Cancer	76	0.0%
Glaucoma	1,972	0.5%
Heart Failure	420	0.1%
Hip / Pelvic Fracture	165	0.0%
Hyperlipidemia	26,107	7.1%
Hypertension	27,308	7.5%
Ischemic Heart Disease	1,718	0.5%
Lung Cancer	56	0.0%
Osteoporosis	876	0.2%
Prostate Cancer	240	0.1%
Rheumatoid Arthritis / Osteoarthritis	14,218	3.9%
Stroke / Transient Ischemic Attack	686	0.2%

Table 1j: Baseline table (Any Mixed Amphetamine Salt, 45 Day Gap)

Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	6.7	7.4
Mean number of emergency room encounters (ED)	0.2	0.6
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	0.8	2.6
Mean number of filled prescriptions	10.0	9.9
Mean number of generics	4.7	3.8
Mean number of unique drug classes	4.5	3.4

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 2a: Descriptive statistics of cumulative exposure duration, all episodes, in days								
Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max
SpecGx Mixed Amphetamine Salt, 7 Day Gap	37,344	76.63	88.74	1	37	37	74	1,596
SpecGx Mixed Amphetamine Salt, 14 Day Gap	37,127	85.42	93.15	1	44	44	88	1,607
Aurolife Mixed Amphetamine Salt, 0 Day Gap	178,453	142.91	170.00	1	30	90	180	1,725
Aurolife Mixed Amphetamine Salt, 7 Day Gap	174,764	159.22	182.76	1	37	96	202	1,725
Aurolife Mixed Amphetamine Salt, 14 Day Gap	172,492	172.58	191.52	1	44	102	220	1,725
Any Mixed Amphetamine Salt, 0 Day Gap	413,490	327.05	371.39	1	60	180	441	2,281
Any Mixed Amphetamine Salt, 7 Day Gap	403,431	337.11	374.66	1	67	191	455	2,280
Any Mixed Amphetamine Salt, 14 Day Gap	395,371	345.76	377.53	1	74	197	467	2,281
Any Mixed Amphetamine Salt, 30 Day Gap	379,334	361.55	381.72	1	90	211	488	2,280
Any Mixed Amphetamine Salt, 45 Day Gap	366,484	373.46	384.16	1	105	225	504	2,280

Table 2b: Descriptive statistics of cumulative exposure duration, all episodes, in days, by sex									
Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max	
SpecGx Mixed Amphetamine Salt, 7 Day Gap	37,344	76.63	88.74	1	37	37	74	1,596	
Female	19,784	75.37	86.49	1	37	37	74	1,568	
Male	17,560	78.07	91.19	1	37	37	74	1,596	
Other	0	-	-	-	-	-	-	-	
SpecGx Mixed Amphetamine Salt, 14 Day Gap	37,127	85.42	93.15	1	44	44	88	1,607	
Female	19,659	84.07	90.86	1	44	44	88	1,597	
Male	17,468	86.94	95.64	1	44	44	88	1,607	
Other	0	-	-	-	-	-	-	-	
Aurolife Mixed Amphetamine Salt, 0 Day Gap	178,453	142.91	170.00	1	30	90	180	1,725	
Female	94,728	144.29	169.91	1	30	90	180	1,725	
Male	83,725	141.35	170.09	1	30	87	180	1,721	
Other	0	-	-	-	-	-	-	-	
Aurolife Mixed Amphetamine Salt, 7 Day Gap	174,764	159.22	182.76	1	37	96	202	1,725	
Female	92,727	160.90	182.84	1	37	97	206	1,725	
Male	82,037	157.33	182.65	1	37	91	197	1,721	
Other	0	-	-	-	-	-	-	-	
Aurolife Mixed Amphetamine Salt, 14 Day Gap	172,492	172.58	191.52	1	44	102	220	1,725	
Female	91,464	174.33	191.55	1	44	104	222	1,725	
Male	81,028	170.60	191.47	1	44	97	216	1,721	
Other	0	-	-	-	-	-	-	-	
Any Mixed Amphetamine Salt, 0 Day Gap	413,490	327.05	371.39	1	60	180	441	2,281	
Female	209,346	335.77	376.45	1	60	180	456	2,281	
Male	204,144	318.10	365.92	1	60	180	420	2,280	
Other	0	-	-	-	-	-	-	-	
Any Mixed Amphetamine Salt, 7 Day Gap	403,431	337.11	374.66	1	67	191	455	2,280	
Female	204,023	346.00	379.92	1	70	195	472	2,280	
Male	199,408	328.02	368.97	1	67	187	438	2,279	
Other	0	-	-	-	-	-	-	-	
Any Mixed Amphetamine Salt, 14 Day Gap	395,371	345.76	377.53	1	74	197	467	2,281	
Female	199,658	354.65	382.95	1	74	208	485	2,281	
Male	195,713	336.69	371.69	1	74	194	448	2,279	
Other	0	-	-	-	-	-	-	-	
Any Mixed Amphetamine Salt, 30 Day Gap	379,334	361.55	381.72	1	90	211	488	2,280	
Female	190,880	370.40	387.48	1	90	221	507	2,280	
Male	188,454	352.57	375.59	1	90	210	472	2,279	
Other	0	-	-	-	-	-	-	-	
Any Mixed Amphetamine Salt, 45 Day Gap	366,484	373.46	384.16	1	105	225	504	2,280	
Female	183,932	382.10	389.85	1	105	231	520	2,280	

Table 2b: Descriptive statistics of cumulative exposure duration, all episodes, in days, by sex								
Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max
Male	182,552	364.77	378.14	1	105	224	488	2,279
Other	0	-	-	-	-	-	-	-

Table 2c: Descriptive statistics of cumulative exposure duration, all episodes, in days, by age group (years)								
Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max
SpecGx Mixed Amphetamine Salt, 7 Day Gap	37,344	76.63	88.74	1	37	37	74	1,596
00-01	0	-	-	-	-	-	-	-
02-04	6	84.00	44.57	37	37	86	111	148
05-09	498	86.64	110.71	1	37	37	83	958
10-14	1,311	81.71	90.86	2	37	37	90	987
15-18	1,698	76.56	85.17	1	37	37	74	1,118
19-21	2,543	73.48	83.13	1	37	37	74	1,056
22-44	22,684	74.39	85.07	1	37	37	74	1,596
45-64	8,401	81.77	96.93	1	37	37	97	1,353
65-74	187	98.89	138.48	2	37	37	97	1,042
75+	16	88.69	77.63	12	37	61	122	306
SpecGx Mixed Amphetamine Salt, 14 Day Gap	37,127	85.42	93.15	1	44	44	88	1,607
00-01	0	-	-	-	-	-	-	-
02-04	6	97.17	51.55	44	44	96	132	171
05-09	495	96.01	116.22	1	44	44	93	972
10-14	1,307	91.65	97.48	2	44	44	97	1,034
15-18	1,691	86.32	91.06	1	44	44	88	1,140
19-21	2,522	82.18	86.33	1	44	44	88	929
22-44	22,566	82.86	88.98	1	44	44	88	1,607
45-64	8,340	90.98	102.16	1	44	44	104	1,426
65-74	184	108.24	144.44	2	44	44	104	1,110
75+	16	97.31	81.57	12	44	65	135	320
Aurolife Mixed Amphetamine Salt, 0 Day Gap	178,453	142.91	170.00	1	30	90	180	1,725
00-01	2	60.00	42.43	30	30	60	90	90
02-04	189	107.97	166.39	5	30	60	120	1,350
05-09	5,618	114.23	144.23	1	30	60	130	1,527
10-14	9,164	113.30	140.15	1	30	60	132	1,575
15-18	10,689	115.30	138.83	1	30	60	140	1,618
19-21	14,662	137.04	164.00	1	30	82	180	1,690
22-44	104,803	144.39	170.49	1	30	90	180	1,725
45-64	32,617	163.09	187.81	1	30	90	210	1,676
65-74	645	152.47	180.01	1	30	90	206	1,330
75+	64	164.41	182.13	1	30	100	221	965
Aurolife Mixed Amphetamine Salt, 7 Day Gap	174,764	159.22	182.76	1	37	96	202	1,725
00-01	2	55.50	26.16	37	37	56	74	74
02-04	187	122.12	178.82	5	37	67	136	1,435
05-09	5,556	129.18	155.15	1	37	74	148	1,605
10-14	9,056	128.53	152.08	1	37	74	148	1,622

Table 2c: Descriptive statistics of cumulative exposure duration, all episodes, in days, by age group (years)									
Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max	
15-18	10,593	131.50	151.48	1	37	74	156	1,541	
19-21	14,486	155.29	178.43	1	37	90	194	1,690	
22-44	102,304	160.28	183.09	1	37	97	204	1,725	
45-64	31,895	180.81	201.33	1	37	107	238	1,686	
65-74	622	167.65	190.14	1	37	97	220	1,393	
75+	63	175.48	174.26	8	37	111	253	838	
Aurolife Mixed Amphetamine Salt, 14 Day Gap	172,492	172.58	191.52	1	44	102	220	1,725	
00-01	2	65.50	30.41	44	44	66	87	87	
02-04	185	132.01	185.18	5	44	74	150	1,488	
05-09	5,511	141.53	163.11	1	44	86	172	1,647	
10-14	8,986	141.36	160.67	1	44	88	174	1,644	
15-18	10,518	145.39	161.00	1	44	88	176	1,583	
19-21	14,358	170.24	188.53	1	44	96	214	1,690	
22-44	100,834	173.36	191.80	1	44	104	220	1,725	
45-64	31,421	194.70	210.05	1	44	118	258	1,704	
65-74	615	180.04	197.57	1	44	104	237	1,446	
75+	62	180.82	174.11	15	44	122	254	885	
Any Mixed Amphetamine Salt, 0 Day Gap	413,490	327.05	371.39	1	60	180	441	2,281	
00-01	6	73.50	57.67	21	30	60	90	180	
02-04	984	241.03	313.75	1	60	120	279	1,995	
05-09	23,526	253.74	319.09	1	60	120	319	2,279	
10-14	33,973	247.96	305.76	1	60	120	300	2,273	
15-18	39,407	288.20	351.22	1	60	150	360	2,278	
19-21	44,524	365.06	401.15	1	74	200	506	2,279	
22-44	209,174	335.59	369.95	1	70	188	455	2,281	
45-64	60,424	369.85	405.58	1	72	210	518	2,275	
65-74	1,317	304.80	347.24	1	60	180	420	2,102	
75+	155	275.60	316.06	1	60	120	377	1,554	
Any Mixed Amphetamine Salt, 7 Day Gap	403,431	337.11	374.66	1	67	191	455	2,280	
00-01	5	59.40	32.29	21	37	67	67	105	
02-04	979	249.82	316.43	1	67	127	292	1,995	
05-09	23,233	263.65	321.99	1	67	134	333	2,279	
10-14	33,492	260.08	310.59	1	67	134	325	2,273	
15-18	38,918	300.97	356.29	1	67	157	385	2,278	
19-21	43,772	377.41	404.69	1	76	213	522	2,274	
22-44	203,064	344.55	372.84	1	74	201	469	2,280	
45-64	58,540	380.57	409.29	1	74	220	535	2,275	
65-74	1,276	313.69	348.70	2	67	184	441	2,102	

Table 2c: Descriptive statistics of cumulative exposure duration, all episodes, in days, by age group (years)								
Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max
75+	152	290.68	326.25	8	67	134	391	1,554
Any Mixed Amphetamine Salt, 14 Day Gap	395,371	345.76	377.53	1	74	197	467	2,281
00-01	5	66.40	36.90	21	44	74	74	119
02-04	976	255.74	316.93	1	74	134	296	1,995
05-09	23,009	272.58	325.18	1	74	138	347	2,279
10-14	33,081	270.87	315.32	1	74	148	342	2,273
15-18	38,479	312.70	361.02	1	74	167	402	2,278
19-21	43,112	388.17	407.77	1	88	222	538	2,278
22-44	198,277	351.91	375.05	1	78	208	480	2,281
45-64	57,038	389.76	413.03	1	82	226	548	2,275
65-74	1,247	322.36	353.12	2	74	192	444	2,102
75+	147	301.51	328.12	13	74	148	407	1,554
Any Mixed Amphetamine Salt, 30 Day Gap	379,334	361.55	381.72	1	90	211	488	2,280
00-01	5	80.00	43.48	21	60	90	90	139
02-04	970	269.75	320.23	1	90	150	314	1,995
05-09	22,571	289.43	330.69	1	90	150	369	2,279
10-14	32,242	290.98	323.78	1	90	165	369	2,273
15-18	37,535	333.77	367.92	1	90	182	431	2,278
19-21	41,858	408.55	412.68	1	94	248	570	2,278
22-44	188,843	365.55	378.20	1	90	224	500	2,280
45-64	54,000	404.96	417.76	1	90	242	569	2,275
65-74	1,170	337.59	360.39	2	90	210	461	2,102
75+	140	322.27	338.72	13	90	177	435	1,554
Any Mixed Amphetamine Salt, 45 Day Gap	366,484	373.46	384.16	1	105	225	504	2,280
00-01	5	92.00	48.76	21	75	105	105	154
02-04	968	281.55	322.04	1	105	159	331	1,995
05-09	22,187	302.30	333.14	1	105	165	387	2,279
10-14	31,465	306.56	328.72	1	105	180	391	2,273
15-18	36,663	350.69	373.61	1	105	210	456	2,278
19-21	40,689	423.68	416.08	1	105	267	587	2,278
22-44	181,660	375.88	380.07	1	105	233	511	2,280
45-64	51,588	415.34	419.63	1	105	255	582	2,279
65-74	1,127	348.39	357.36	2	105	225	489	2,102
75+	132	331.76	339.78	13	105	178	440	1,554

Table 3a: Descriptive statistics of first exposure episode duration, in days								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
SpecGx Mixed Amphetamine Salt, 7 Day Gap	37,344	48.25	39.81	1	37	37	37	1,027
SpecGx Mixed Amphetamine Salt, 14 Day Gap	37,127	57.53	46.14	1	44	44	44	1,027
Aurolife Mixed Amphetamine Salt, 0 Day Gap	178,453	43.36	52.59	1	30	30	30	1,725
Aurolife Mixed Amphetamine Salt, 7 Day Gap	174,764	64.87	76.87	1	37	37	67	1,725
Aurolife Mixed Amphetamine Salt, 14 Day Gap	172,492	79.31	88.33	1	44	44	81	1,725
Any Mixed Amphetamine Salt, 0 Day Gap	413,490	177.32	284.24	1	30	60	180	2,281
Any Mixed Amphetamine Salt, 7 Day Gap	403,431	200.72	294.26	1	61	67	197	2,280
Any Mixed Amphetamine Salt, 14 Day Gap	395,371	218.39	301.68	1	74	85	236	2,281
Any Mixed Amphetamine Salt, 30 Day Gap	379,334	251.28	314.35	1	90	121	283	2,280
Any Mixed Amphetamine Salt, 45 Day Gap	366,484	277.45	324.66	1	105	151	327	2,280

Table 3b: Descriptive statistics of first exposure episode duration, in days, by sex									
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max	
SpecGx Mixed Amphetamine Salt, 7 Day Gap	37,344	48.25	39.81	1	37	37	37	1,027	
Female	19,784	48.00	40.50	1	37	37	37	1,027	
Male	17,560	48.53	39.01	1	37	37	37	878	
Other	0	-	-	-	-	-	-	-	
SpecGx Mixed Amphetamine Salt, 14 Day Gap	37,127	57.53	46.14	1	44	44	44	1,027	
Female	19,659	57.28	46.54	1	44	44	44	1,027	
Male	17,468	57.80	45.67	1	44	44	44	929	
Other	0	-	-	-	-	-	-	-	
Aurolife Mixed Amphetamine Salt, 0 Day Gap	178,453	43.36	52.59	1	30	30	30	1,725	
Female	94,728	43.18	52.48	1	30	30	30	1,725	
Male	83,725	43.57	52.72	1	30	30	30	1,721	
Other	0	-	-	-	-	-	-	-	
Aurolife Mixed Amphetamine Salt, 7 Day Gap	174,764	64.87	76.87	1	37	37	67	1,725	
Female	92,727	64.53	76.40	1	37	37	67	1,725	
Male	82,037	65.25	77.41	1	37	37	67	1,721	
Other	0	-	-	-	-	-	-	-	
Aurolife Mixed Amphetamine Salt, 14 Day Gap	172,492	79.31	88.33	1	44	44	81	1,725	
Female	91,464	79.04	87.70	1	44	44	81	1,725	
Male	81,028	79.62	89.04	1	44	44	81	1,721	
Other	0	-	-	-	-	-	-	-	
Any Mixed Amphetamine Salt, 0 Day Gap	413,490	177.32	284.24	1	30	60	180	2,281	
Female	209,346	180.01	287.38	1	30	60	180	2,281	
Male	204,144	174.57	280.96	1	30	60	180	2,280	
Other	0	-	-	-	-	-	-	-	
Any Mixed Amphetamine Salt, 7 Day Gap	403,431	200.72	294.26	1	61	67	197	2,280	
Female	204,023	204.01	297.83	1	63	67	207	2,280	
Male	199,408	197.34	290.52	1	59	67	192	2,279	
Other	0	-	-	-	-	-	-	-	
Any Mixed Amphetamine Salt, 14 Day Gap	395,371	218.39	301.68	1	74	85	236	2,281	
Female	199,658	222.18	305.54	1	74	87	245	2,281	
Male	195,713	214.52	297.64	1	74	82	226	2,279	
Other	0	-	-	-	-	-	-	-	
Any Mixed Amphetamine Salt, 30 Day Gap	379,334	251.28	314.35	1	90	121	283	2,280	
Female	190,880	256.05	318.59	1	90	126	294	2,280	
Male	188,454	246.46	309.92	1	90	120	272	2,279	
Other	0	-	-	-	-	-	-	-	
Any Mixed Amphetamine Salt, 45 Day Gap	366,484	277.45	324.66	1	105	151	327	2,280	
Female	183,932	283.22	329.53	1	105	158	340	2,280	



Table 3b: Descriptive statistics of first exposure episode duration, in days, by sex								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Male	182,552	271.65	319.57	1	105	145	315	2,279
Other	0	-	-	-	-	-	-	-

Table 3c: Descriptive statistics of first exposure episode duration, in days, by age group (years)								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
SpecGx Mixed Amphetamine Salt, 7 Day Gap	37,344	48.25	39.81	1	37	37	37	1,027
00-01	0	-	-	-	-	-	-	-
02-04	6	42.00	12.25	37	37	37	37	67
05-09	498	50.52	54.37	1	37	37	37	878
10-14	1,311	48.54	37.23	2	37	37	37	549
15-18	1,698	45.31	30.16	1	37	37	37	554
19-21	2,543	45.79	31.62	1	37	37	37	492
22-44	22,684	48.05	39.32	1	37	37	37	1,027
45-64	8,401	49.83	43.90	1	37	37	37	911
65-74	187	53.19	50.22	2	37	37	52	495
75+	16	55.56	32.95	12	37	37	82	132
SpecGx Mixed Amphetamine Salt, 14 Day Gap	37,127	57.53	46.14	1	44	44	44	1,027
00-01	0	-	-	-	-	-	-	-
02-04	6	49.00	12.25	44	44	44	44	74
05-09	495	63.11	65.25	1	44	44	44	878
10-14	1,307	57.49	40.23	2	44	44	44	556
15-18	1,691	55.71	38.12	1	44	44	44	561
19-21	2,522	54.94	41.74	1	44	44	44	929
22-44	22,566	57.05	44.84	1	44	44	44	1,027
45-64	8,340	59.50	51.16	1	44	44	44	918
65-74	184	63.14	60.47	2	44	44	74	495
75+	16	66.63	36.87	12	44	44	101	139
Aurolife Mixed Amphetamine Salt, 0 Day Gap	178,453	43.36	52.59	1	30	30	30	1,725
00-01	2	30.00	0.00	30	30	30	30	30
02-04	189	39.46	31.46	5	30	30	30	252
05-09	5,618	39.41	43.57	1	30	30	30	1,099
10-14	9,164	40.03	47.54	1	30	30	30	1,333
15-18	10,689	39.06	35.97	1	30	30	30	867
19-21	14,662	40.62	47.77	1	30	30	30	1,690
22-44	104,803	43.74	53.87	1	30	30	30	1,725
45-64	32,617	46.28	57.59	1	30	30	30	1,564
65-74	645	48.88	48.86	1	30	30	60	542
75+	64	51.17	46.51	1	30	30	60	302
Aurolife Mixed Amphetamine Salt, 7 Day Gap	174,764	64.87	76.87	1	37	37	67	1,725
00-01	2	37.00	0.00	37	37	37	37	37
02-04	187	59.17	68.17	5	37	37	67	701
05-09	5,556	57.28	60.44	1	37	37	67	1,099
10-14	9,056	56.10	62.95	1	37	37	63	1,333

Table 3c: Descriptive statistics of first exposure episode duration, in days, by age group (years)									
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max	
15-18	10,593	54.70	54.03	1	37	37	56	1,161	
19-21	14,486	58.73	67.37	1	37	37	67	1,690	
22-44	102,304	66.10	78.79	1	37	37	68	1,725	
45-64	31,895	70.78	85.97	1	37	37	71	1,564	
65-74	622	71.37	81.16	1	37	37	72	825	
75+	63	67.87	56.66	8	37	37	97	309	
Aurolife Mixed Amphetamine Salt, 14 Day Gap	172,492	79.31	88.33	1	44	44	81	1,725	
00-01	2	44.00	0.00	44	44	44	44	44	
02-04	185	77.28	108.82	5	44	44	75	1,298	
05-09	5,511	70.97	72.94	1	44	44	76	1,099	
10-14	8,986	69.11	71.96	1	44	44	74	1,396	
15-18	10,518	66.48	62.40	1	44	44	74	1,168	
19-21	14,358	72.63	79.44	1	44	44	76	1,690	
22-44	100,834	80.59	90.14	1	44	44	81	1,725	
45-64	31,421	86.83	98.75	1	44	44	102	1,587	
65-74	615	84.95	86.71	1	44	44	104	832	
75+	62	83.53	72.96	15	44	44	104	357	
Any Mixed Amphetamine Salt, 0 Day Gap	413,490	177.32	284.24	1	30	60	180	2,281	
00-01	6	53.50	36.52	21	30	45	60	120	
02-04	984	170.42	253.50	1	50	60	180	1,995	
05-09	23,526	143.51	237.43	1	30	60	120	2,279	
10-14	33,973	123.53	207.51	1	30	60	120	2,273	
15-18	39,407	133.85	231.17	1	30	60	120	2,278	
19-21	44,524	185.56	303.00	1	40	60	180	2,279	
22-44	209,174	193.45	295.97	1	37	60	197	2,281	
45-64	60,424	188.12	307.21	1	30	60	180	2,275	
65-74	1,317	142.11	214.21	1	30	60	120	2,102	
75+	155	150.75	241.44	1	30	60	120	1,554	
Any Mixed Amphetamine Salt, 7 Day Gap	403,431	200.72	294.26	1	61	67	197	2,280	
00-01	5	45.80	20.43	21	37	37	67	67	
02-04	979	182.50	252.91	1	67	67	187	1,995	
05-09	23,233	162.94	244.81	1	42	67	159	2,279	
10-14	33,492	141.39	216.44	1	37	67	127	2,273	
15-18	38,918	151.69	240.11	1	42	67	128	2,278	
19-21	43,772	209.52	314.25	1	67	67	190	2,273	
22-44	203,064	218.28	305.77	1	67	81	247	2,280	
45-64	58,540	215.98	319.03	1	59	69	221	2,275	
65-74	1,276	161.96	222.79	2	37	67	187	2,102	

Table 3c: Descriptive statistics of first exposure episode duration, in days, by age group (years)									
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max	
75+	152	164.22	241.06	8	56	67	143	1,554	
Any Mixed Amphetamine Salt, 14 Day Gap	395,371	218.39	301.68	1	74	85	236	2,281	
00-01	5	51.40	22.67	21	44	44	74	74	
02-04	976	195.01	253.96	1	74	80	197	1,995	
05-09	23,009	178.89	253.74	1	58	74	194	2,279	
10-14	33,081	156.56	224.29	1	45	74	147	2,273	
15-18	38,479	167.38	247.52	1	61	74	155	2,278	
19-21	43,112	228.15	322.06	1	74	86	231	2,278	
22-44	198,277	236.03	312.36	1	74	104	266	2,281	
45-64	57,038	237.18	328.90	1	74	101	254	2,275	
65-74	1,247	180.24	234.80	2	48	74	194	2,102	
75+	147	188.92	254.19	13	74	79	194	1,554	
Any Mixed Amphetamine Salt, 30 Day Gap	379,334	251.28	314.35	1	90	121	283	2,280	
00-01	5	80.00	43.48	21	60	90	90	139	
02-04	970	217.03	259.79	1	90	109	232	1,995	
05-09	22,571	207.17	265.52	1	80	90	214	2,279	
10-14	32,242	185.87	237.43	1	74	90	206	2,273	
15-18	37,535	199.32	261.43	1	89	90	210	2,278	
19-21	41,858	265.54	337.92	1	90	127	290	2,278	
22-44	188,843	268.49	323.60	1	90	146	329	2,280	
45-64	54,000	275.00	344.53	1	90	134	324	2,275	
65-74	1,170	220.16	276.49	2	61	112	244	2,102	
75+	140	242.85	283.83	13	90	117	292	1,554	
Any Mixed Amphetamine Salt, 45 Day Gap	366,484	277.45	324.66	1	105	151	327	2,280	
00-01	5	92.00	48.76	21	75	105	105	154	
02-04	968	234.25	269.23	1	105	122	252	1,995	
05-09	22,187	230.13	274.72	1	91	110	255	2,279	
10-14	31,465	210.17	247.17	1	89	105	225	2,273	
15-18	36,663	227.55	277.74	1	105	111	235	2,278	
19-21	40,689	295.94	350.50	1	105	161	345	2,278	
22-44	181,660	293.42	332.59	1	105	165	358	2,280	
45-64	51,588	305.14	356.38	1	105	165	368	2,279	
65-74	1,127	245.02	284.48	1	78	135	285	2,102	
75+	132	250.78	286.41	13	105	110	297	1,554	

Table 4a: Descriptive statistics of all exposure episode durations, in days								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
SpecGx Mixed Amphetamine Salt, 7 Day Gap	57,517	49.76	42.90	1	37	37	37	1,027
SpecGx Mixed Amphetamine Salt, 14 Day Gap	53,580	59.19	49.35	1	44	44	44	1,027
Aurolife Mixed Amphetamine Salt, 0 Day Gap	601,142	42.42	46.77	1	30	30	30	1,725
Aurolife Mixed Amphetamine Salt, 7 Day Gap	445,878	62.41	69.31	1	37	37	67	1,725
Aurolife Mixed Amphetamine Salt, 14 Day Gap	387,638	76.79	81.70	1	44	44	80	1,725
Any Mixed Amphetamine Salt, 0 Day Gap	1,036,740	130.44	228.09	1	30	60	120	2,281
Any Mixed Amphetamine Salt, 7 Day Gap	854,392	159.18	246.93	1	37	67	140	2,280
Any Mixed Amphetamine Salt, 14 Day Gap	754,666	181.14	260.11	1	44	74	194	2,281
Any Mixed Amphetamine Salt, 30 Day Gap	616,794	222.35	282.42	1	80	103	240	2,280
Any Mixed Amphetamine Salt, 45 Day Gap	538,239	254.29	298.99	1	101	135	286	2,280

Table 4b: Descriptive statistics of all exposure episode durations, in days, by sex								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
SpecGx Mixed Amphetamine Salt, 7 Day Gap	57,517	49.76	42.90	1	37	37	37	1,027
Female	30,255	49.28	42.03	1	37	37	37	1,027
Male	27,262	50.28	43.83	1	37	37	37	929
Other	0	-	-	-	-	-	-	-
SpecGx Mixed Amphetamine Salt, 14 Day Gap	53,580	59.19	49.35	1	44	44	44	1,027
Female	28,175	58.66	48.49	1	44	44	44	1,027
Male	25,405	59.78	50.28	1	44	44	49	929
Other	0	-	-	-	-	-	-	-
Aurolife Mixed Amphetamine Salt, 0 Day Gap	601,142	42.42	46.77	1	30	30	30	1,725
Female	324,028	42.18	46.23	1	30	30	30	1,725
Male	277,114	42.71	47.39	1	30	30	30	1,721
Other	0	-	-	-	-	-	-	-
Aurolife Mixed Amphetamine Salt, 7 Day Gap	445,878	62.41	69.31	1	37	37	67	1,725
Female	240,294	62.09	68.71	1	37	37	67	1,725
Male	205,584	62.78	70.00	1	37	37	67	1,721
Other	0	-	-	-	-	-	-	-
Aurolife Mixed Amphetamine Salt, 14 Day Gap	387,638	76.79	81.70	1	44	44	80	1,725
Female	208,442	76.49	81.03	1	44	44	80	1,725
Male	179,196	77.14	82.47	1	44	44	80	1,721
Other	0	-	-	-	-	-	-	-
Any Mixed Amphetamine Salt, 0 Day Gap	1,036,740	130.44	228.09	1	30	60	120	2,281
Female	535,123	131.36	229.56	1	30	60	120	2,281
Male	501,617	129.46	226.50	1	30	60	120	2,280
Other	0	-	-	-	-	-	-	-
Any Mixed Amphetamine Salt, 7 Day Gap	854,392	159.18	246.93	1	37	67	140	2,280
Female	440,207	160.36	248.71	1	37	67	143	2,280
Male	414,185	157.93	245.01	1	37	67	138	2,279
Other	0	-	-	-	-	-	-	-
Any Mixed Amphetamine Salt, 14 Day Gap	754,666	181.14	260.11	1	44	74	194	2,281
Female	387,305	182.82	262.27	1	44	74	194	2,281
Male	367,361	179.37	257.81	1	44	74	189	2,279
Other	0	-	-	-	-	-	-	-
Any Mixed Amphetamine Salt, 30 Day Gap	616,794	222.35	282.42	1	80	103	240	2,280
Female	313,858	225.27	285.48	1	81	105	244	2,280
Male	302,936	219.33	279.18	1	80	101	234	2,279
Other	0	-	-	-	-	-	-	-
Any Mixed Amphetamine Salt, 45 Day Gap	538,239	254.29	298.99	1	101	135	286	2,280
Female	272,049	258.34	302.86	1	102	136	295	2,280



Table 4b: Descriptive statistics of all exposure episode durations, in days, by sex								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Male	266,190	250.15	294.94	1	100	135	285	2,279
Other	0	-	-	-	-	-	-	-

Table 4c: Descriptive statistics of all exposure episode durations, in days, by age group (years)								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
SpecGx Mixed Amphetamine Salt, 7 Day Gap	57,517	49.76	42.90	1	37	37	37	1,027
00-01	0	-	-	-	-	-	-	-
02-04	12	42.00	11.68	37	37	37	37	67
05-09	797	54.14	57.15	1	37	37	41	878
10-14	2,176	49.23	38.31	2	37	37	37	549
15-18	2,766	47.00	32.41	1	37	37	37	554
19-21	3,908	47.81	38.72	1	37	37	37	929
22-44	34,049	49.56	42.64	1	37	37	37	1,027
45-64	13,477	50.97	45.62	1	37	37	37	911
65-74	308	60.04	62.43	2	37	37	67	495
75+	24	59.13	35.56	12	37	37	97	136
SpecGx Mixed Amphetamine Salt, 14 Day Gap	53,580	59.19	49.35	1	44	44	44	1,027
00-01	0	-	-	-	-	-	-	-
02-04	12	48.58	11.96	39	44	44	44	74
05-09	727	65.37	64.19	1	44	44	74	878
10-14	2,005	59.74	47.66	2	44	44	49	824
15-18	2,548	57.29	40.26	1	44	44	44	561
19-21	3,635	57.01	43.81	1	44	44	44	929
22-44	31,851	58.71	48.75	1	44	44	44	1,027
45-64	12,498	60.71	52.62	1	44	44	59	918
65-74	282	70.63	70.14	2	44	44	74	495
75+	22	70.77	38.32	12	44	44	104	143
Aurolife Mixed Amphetamine Salt, 0 Day Gap	601,142	42.42	46.77	1	30	30	30	1,725
00-01	4	30.00	0.00	30	30	30	30	30
02-04	483	42.25	46.66	2	30	30	30	660
05-09	15,857	40.47	44.45	1	30	30	30	1,300
10-14	25,714	40.38	43.60	1	30	30	30	1,333
15-18	31,176	39.53	37.27	1	30	30	30	1,588
19-21	49,681	40.44	43.38	1	30	30	30	1,690
22-44	355,191	42.60	47.34	1	30	30	30	1,725
45-64	120,759	44.05	49.36	1	30	30	30	1,564
65-74	2,061	47.72	50.26	1	30	30	60	630
75+	216	48.71	42.26	1	30	30	60	302
Aurolife Mixed Amphetamine Salt, 7 Day Gap	445,878	62.41	69.31	1	37	37	67	1,725
00-01	3	37.00	0.00	37	37	37	37	37
02-04	360	63.44	68.07	2	37	37	67	701
05-09	12,401	57.88	62.31	1	37	37	67	1,335
10-14	20,725	56.16	59.30	1	37	37	67	1,356

Table 4c: Descriptive statistics of all exposure episode durations, in days, by age group (years)									
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max	
15-18	25,430	54.78	51.99	1	37	37	67	1,161	
19-21	38,408	58.57	62.99	1	37	37	67	1,690	
22-44	259,341	63.23	70.69	1	37	37	67	1,725	
45-64	87,526	65.89	74.74	1	37	37	69	1,564	
65-74	1,521	68.56	74.84	1	37	37	72	825	
75+	163	67.82	54.56	5	37	37	97	373	
Aurolife Mixed Amphetamine Salt, 14 Day Gap	387,638	76.79	81.70	1	44	44	80	1,725	
00-01	3	43.67	0.58	43	43	44	44	44	
02-04	308	79.29	99.26	2	44	44	79	1,298	
05-09	10,856	71.85	73.47	1	44	44	78	1,335	
10-14	18,328	69.31	69.08	1	44	44	76	1,396	
15-18	22,764	67.18	61.47	1	44	44	75	1,299	
19-21	33,705	72.52	75.00	1	44	44	78	1,690	
22-44	225,175	77.63	83.12	1	44	44	80	1,725	
45-64	75,032	81.53	88.66	1	44	44	86	1,587	
65-74	1,330	83.25	88.39	1	44	44	104	890	
75+	137	81.83	71.10	5	44	44	104	411	
Any Mixed Amphetamine Salt, 0 Day Gap	1,036,740	130.44	228.09	1	30	60	120	2,281	
00-01	9	49.00	30.89	21	30	30	60	120	
02-04	1,609	147.41	229.95	1	30	60	128	1,995	
05-09	51,754	115.34	199.49	1	30	60	101	2,279	
10-14	84,114	100.15	171.48	1	30	60	90	2,273	
15-18	102,177	111.15	195.86	1	30	60	90	2,278	
19-21	118,635	137.01	242.79	1	30	60	120	2,279	
22-44	502,944	139.57	238.38	1	30	60	120	2,281	
45-64	171,657	130.19	235.45	1	30	60	100	2,275	
65-74	3,453	116.25	187.25	1	30	60	90	2,102	
75+	388	110.10	182.84	1	30	60	90	1,554	
Any Mixed Amphetamine Salt, 7 Day Gap	854,392	159.18	246.93	1	37	67	140	2,280	
00-01	6	49.50	20.39	21	37	52	67	68	
02-04	1,422	172.00	242.61	1	53	67	187	1,995	
05-09	43,213	141.75	216.24	1	37	67	127	2,279	
10-14	72,034	120.92	185.06	1	37	67	127	2,273	
15-18	88,490	132.37	209.67	1	37	67	127	2,278	
19-21	100,054	165.11	260.86	1	37	67	137	2,273	
22-44	409,484	170.86	258.29	1	37	67	173	2,280	
45-64	136,525	163.18	258.67	1	37	67	139	2,275	
65-74	2,838	141.04	201.57	1	37	67	130	2,102	

Table 4c: Descriptive statistics of all exposure episode durations, in days, by age group (years)									
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max	
75+	326	135.53	202.74	8	37	67	127	1,554	
Any Mixed Amphetamine Salt, 14 Day Gap	754,666	181.14	260.11	1	44	74	194	2,281	
00-01	6	55.33	22.45	21	44	59	74	75	
02-04	1,304	191.41	251.43	1	74	78	196	1,995	
05-09	38,938	161.07	227.95	1	44	74	159	2,279	
10-14	64,827	138.22	195.82	1	44	74	134	2,273	
15-18	80,033	150.34	220.85	1	44	74	135	2,278	
19-21	89,237	187.53	274.24	1	52	74	194	2,278	
22-44	359,729	193.97	271.34	1	50	74	196	2,281	
45-64	117,820	188.69	275.71	1	44	74	194	2,275	
65-74	2,489	161.50	216.96	1	44	74	177	2,102	
75+	283	156.61	218.84	12	44	74	142	1,554	
Any Mixed Amphetamine Salt, 30 Day Gap	616,794	222.35	282.42	1	80	103	240	2,280	
00-01	5	80.00	43.48	21	60	90	90	139	
02-04	1,186	220.62	264.76	1	90	111	238	1,995	
05-09	33,160	197.01	247.03	1	72	90	210	2,279	
10-14	54,097	173.42	215.50	1	60	90	180	2,273	
15-18	67,108	186.69	241.43	1	74	90	193	2,278	
19-21	74,111	230.75	297.42	1	90	106	239	2,278	
22-44	292,093	236.34	293.28	1	83	117	270	2,280	
45-64	92,822	235.59	303.24	1	78	110	257	2,275	
65-74	1,983	199.18	247.45	1	60	90	216	2,102	
75+	229	197.02	242.79	12	60	90	210	1,554	
Any Mixed Amphetamine Salt, 45 Day Gap	538,239	254.29	298.99	1	101	135	286	2,280	
00-01	5	92.00	48.76	21	75	105	105	154	
02-04	1,143	238.44	273.77	1	105	125	261	1,995	
05-09	29,982	223.70	260.61	1	89	112	249	2,279	
10-14	47,931	201.25	230.31	1	83	105	225	2,273	
15-18	59,288	216.86	259.36	1	96	106	225	2,278	
19-21	65,020	265.14	315.30	1	105	136	292	2,278	
22-44	254,696	268.10	308.93	1	101	147	320	2,280	
45-64	78,256	273.80	324.24	1	104	141	317	2,279	
65-74	1,718	228.54	263.02	1	75	116	269	2,102	
75+	200	218.96	260.32	12	75	105	225	1,554	

Table 5a: Descriptive statistics of days supplied per dispensing									
Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max	
SpecGx Mixed Amphetamine Salt, 7 Day Gap	82,313	29.98	8.86	1	30	30	30	195	
SpecGx Mixed Amphetamine Salt, 14 Day Gap	81,283	29.98	8.88	1	30	30	30	195	
Aurolife Mixed Amphetamine Salt, 0 Day Gap	822,676	31.00	11.56	1	30	30	30	607	
Aurolife Mixed Amphetamine Salt, 7 Day Gap	793,739	31.00	11.58	1	30	30	30	607	
Aurolife Mixed Amphetamine Salt, 14 Day Gap	777,390	31.00	11.59	1	30	30	30	607	
Any Mixed Amphetamine Salt, 0 Day Gap	2,660,175	50.84	22.20	1	30	60	60	1,461	
Any Mixed Amphetamine Salt, 7 Day Gap	2,567,713	51.02	22.22	1	30	60	60	1,461	
Any Mixed Amphetamine Salt, 14 Day Gap	2,499,230	51.13	22.23	1	30	60	60	1,461	
Any Mixed Amphetamine Salt, 30 Day Gap	2,370,695	51.28	22.23	1	30	60	60	1,461	
Any Mixed Amphetamine Salt, 45 Day Gap	2,274,573	51.38	22.22	1	30	60	60	1,461	

Table 5b: Descriptive statistics of days supplied per dispensing, by sex									
Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max	
SpecGx Mixed Amphetamine Salt, 7 Day Gap	82,313	29.98	8.86	1	30	30	30	195	
Female	42,795	30.01	8.97	1	30	30	30	195	
Male	39,518	29.94	8.75	1	30	30	30	120	
Other	0	-	-	-	-	-	-	-	
SpecGx Mixed Amphetamine Salt, 14 Day Gap	81,283	29.98	8.88	1	30	30	30	195	
Female	42,234	30.01	8.98	1	30	30	30	195	
Male	39,049	29.96	8.77	1	30	30	30	120	
Other	0	-	-	-	-	-	-	-	
Aurolife Mixed Amphetamine Salt, 0 Day Gap	822,676	31.00	11.56	1	30	30	30	607	
Female	441,581	30.95	11.42	1	30	30	30	300	
Male	381,095	31.05	11.71	1	30	30	30	607	
Other	0	-	-	-	-	-	-	-	
Aurolife Mixed Amphetamine Salt, 7 Day Gap	793,739	31.00	11.58	1	30	30	30	607	
Female	425,923	30.95	11.45	1	30	30	30	300	
Male	367,816	31.06	11.74	1	30	30	30	607	
Other	0	-	-	-	-	-	-	-	
Aurolife Mixed Amphetamine Salt, 14 Day Gap	777,390	31.00	11.59	1	30	30	30	607	
Female	416,593	30.95	11.45	1	30	30	30	300	
Male	360,797	31.06	11.75	1	30	30	30	607	
Other	0	-	-	-	-	-	-	-	
Any Mixed Amphetamine Salt, 0 Day Gap	2,660,175	50.84	22.20	1	30	60	60	1,461	
Female	1,379,051	50.97	22.05	1	30	60	60	660	
Male	1,281,124	50.69	22.35	1	30	60	60	1,461	
Other	0	-	-	-	-	-	-	-	
Any Mixed Amphetamine Salt, 7 Day Gap	2,567,713	51.02	22.22	1	30	60	60	1,461	
Female	1,329,758	51.16	22.08	1	30	60	60	660	
Male	1,237,955	50.87	22.38	1	30	60	60	1,461	
Other	0	-	-	-	-	-	-	-	
Any Mixed Amphetamine Salt, 14 Day Gap	2,499,230	51.13	22.23	1	30	60	60	1,461	
Female	1,292,104	51.27	22.09	1	30	60	60	660	
Male	1,207,126	50.98	22.38	1	30	60	60	1,461	
Other	0	-	-	-	-	-	-	-	
Any Mixed Amphetamine Salt, 30 Day Gap	2,370,695	51.28	22.23	1	30	60	60	1,461	
Female	1,220,993	51.43	22.08	1	30	60	60	660	
Male	1,149,702	51.11	22.39	1	30	60	60	1,461	
Other	0	-	-	-	-	-	-	-	
Any Mixed Amphetamine Salt, 45 Day Gap	2,274,573	51.38	22.22	1	30	60	60	1,461	
Female	1,168,064	51.54	22.07	1	30	60	60	660	

Table 5b: Descriptive statistics of days supplied per dispensing, by sex									
Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max	
Male	1,106,509	51.20	22.38	1	30	60	60	1,461	
Other	0	-	-	-	-	-	-	-	-

Table 5c: Descriptive statistics of days supplied per dispensing, by age group (years)									
Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max	
SpecGx Mixed Amphetamine Salt, 7 Day Gap	82,313	29.98	8.86	1	30	30	30	195	
00-01	0	-	-	-	-	-	-	-	
02-04	14	30.00	0.00	30	30	30	30	30	
05-09	1,260	29.77	6.83	1	30	30	30	90	
10-14	3,042	30.23	8.60	1	30	30	30	90	
15-18	3,670	30.19	9.12	1	30	30	30	151	
19-21	5,272	30.29	9.46	1	30	30	30	150	
22-44	48,891	29.77	8.40	1	30	30	30	195	
45-64	19,621	30.29	9.60	1	30	30	30	102	
65-74	510	32.02	15.35	1	30	30	30	180	
75+	33	37.91	22.67	12	30	30	30	90	
SpecGx Mixed Amphetamine Salt, 14 Day Gap	81,283	29.98	8.88	1	30	30	30	195	
00-01	0	-	-	-	-	-	-	-	
02-04	14	30.00	0.00	30	30	30	30	30	
05-09	1,247	29.76	6.86	1	30	30	30	90	
10-14	3,024	30.24	8.62	1	30	30	30	90	
15-18	3,644	30.18	9.13	1	30	30	30	151	
19-21	5,166	30.30	9.47	1	30	30	30	150	
22-44	48,280	29.77	8.41	1	30	30	30	195	
45-64	19,375	30.30	9.64	1	30	30	30	102	
65-74	500	32.06	15.50	1	30	30	30	180	
75+	33	37.91	22.67	12	30	30	30	90	
Aurolife Mixed Amphetamine Salt, 0 Day Gap	822,676	31.00	11.56	1	30	30	30	607	
00-01	4	30.00	0.00	30	30	30	30	30	
02-04	695	29.36	7.52	1	30	30	30	90	
05-09	20,935	30.65	9.96	1	30	30	30	120	
10-14	32,637	31.81	12.95	1	30	30	30	180	
15-18	38,574	31.95	13.60	1	30	30	30	180	
19-21	64,453	31.17	11.60	1	30	30	30	180	
22-44	494,937	30.57	10.61	1	30	30	30	607	
45-64	167,222	31.81	13.28	1	30	30	30	180	
65-74	2,910	33.79	17.70	1	30	30	30	180	
75+	309	34.05	17.58	1	30	30	30	122	
Aurolife Mixed Amphetamine Salt, 7 Day Gap	793,739	31.00	11.58	1	30	30	30	607	
00-01	3	30.00	0.00	30	30	30	30	30	
02-04	688	29.36	7.56	1	30	30	30	90	
05-09	20,484	30.66	10.01	1	30	30	30	120	
10-14	31,972	31.80	12.93	1	30	30	30	180	

Table 5c: Descriptive statistics of days supplied per dispensing, by age group (years)									
Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max	
15-18	37,900	31.96	13.65	1	30	30	30	180	
19-21	63,146	31.18	11.62	1	30	30	30	180	
22-44	475,360	30.57	10.64	1	30	30	30	607	
45-64	161,129	31.81	13.29	1	30	30	30	180	
65-74	2,761	33.87	17.84	1	30	30	30	180	
75+	296	33.47	16.70	1	30	30	30	122	
Aurolife Mixed Amphetamine Salt, 14 Day Gap	777,390	31.00	11.59	1	30	30	30	607	
00-01	3	30.00	0.00	30	30	30	30	30	
02-04	677	29.27	7.34	1	30	30	30	90	
05-09	20,193	30.66	10.02	1	30	30	30	120	
10-14	31,530	31.81	12.95	1	30	30	30	180	
15-18	37,442	31.98	13.68	1	30	30	30	180	
19-21	62,287	31.17	11.61	1	30	30	30	180	
22-44	465,029	30.57	10.64	1	30	30	30	607	
45-64	157,233	31.81	13.31	1	30	30	30	180	
65-74	2,709	33.89	17.91	1	30	30	30	180	
75+	287	32.20	14.68	1	30	30	30	122	
Any Mixed Amphetamine Salt, 0 Day Gap	2,660,175	50.84	22.20	1	30	60	60	1,461	
00-01	10	44.10	16.97	21	30	45	60	60	
02-04	4,707	50.39	20.22	1	30	60	60	200	
05-09	120,226	49.65	21.94	1	30	60	60	600	
10-14	167,326	50.34	24.43	1	30	60	60	600	
15-18	219,037	51.85	24.41	1	30	60	60	540	
19-21	312,547	52.00	22.23	1	30	60	60	480	
22-44	1,388,530	50.56	21.06	1	30	60	60	1,461	
45-64	439,071	50.90	23.50	1	30	60	60	660	
65-74	7,909	50.76	27.96	1	30	60	60	360	
75+	812	52.61	28.46	1	30	60	60	180	
Any Mixed Amphetamine Salt, 7 Day Gap	2,567,713	51.02	22.22	1	30	60	60	1,461	
00-01	7	37.29	15.86	21	30	30	60	60	
02-04	4,692	50.44	20.21	1	30	60	60	200	
05-09	117,832	49.73	21.95	1	30	60	60	600	
10-14	163,724	50.42	24.47	1	30	60	60	600	
15-18	214,938	51.91	24.42	1	30	60	60	540	
19-21	305,334	52.10	22.22	1	30	60	60	480	
22-44	1,333,130	50.79	21.10	1	30	60	60	1,461	
45-64	419,758	51.12	23.51	1	30	60	60	660	
65-74	7,496	51.10	27.66	1	30	60	60	360	



Table 5c: Descriptive statistics of days supplied per dispensing, by age group (years)									
Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max	
75+	802	52.60	28.60	1	30	60	60	180	
Any Mixed Amphetamine Salt, 14 Day Gap	2,499,230	51.13	22.23	1	30	60	60	1,461	
00-01	7	37.29	15.86	21	30	30	60	60	
02-04	4,662	50.40	20.26	1	30	60	60	200	
05-09	116,291	49.77	21.96	1	30	60	60	600	
10-14	160,925	50.48	24.45	1	30	60	60	600	
15-18	211,831	51.96	24.43	1	30	60	60	540	
19-21	299,517	52.17	22.22	1	30	60	60	480	
22-44	1,292,387	50.91	21.09	1	30	60	60	1,461	
45-64	405,591	51.27	23.55	1	30	60	60	660	
65-74	7,247	51.22	27.76	1	30	60	60	360	
75+	772	52.83	28.94	1	30	60	60	180	
Any Mixed Amphetamine Salt, 30 Day Gap	2,370,695	51.28	22.23	1	30	60	60	1,461	
00-01	7	37.29	15.86	21	30	30	60	60	
02-04	4,642	50.42	20.27	1	30	60	60	200	
05-09	113,362	49.83	21.97	1	30	60	60	600	
10-14	155,175	50.59	24.57	1	30	60	60	600	
15-18	204,520	52.04	24.42	1	30	60	60	540	
19-21	288,911	52.25	22.23	1	30	60	60	480	
22-44	1,218,942	51.08	21.06	1	30	60	60	1,461	
45-64	377,764	51.48	23.54	1	30	60	60	660	
65-74	6,634	51.43	27.88	1	30	60	60	360	
75+	738	52.79	29.47	1	30	60	60	180	
Any Mixed Amphetamine Salt, 45 Day Gap	2,274,573	51.38	22.22	1	30	60	60	1,461	
00-01	7	37.29	15.86	21	30	30	60	60	
02-04	4,639	50.43	20.27	1	30	60	60	200	
05-09	110,780	49.87	21.94	1	30	60	60	600	
10-14	150,339	50.63	24.54	1	30	60	60	600	
15-18	198,602	52.11	24.46	1	30	60	60	540	
19-21	279,317	52.30	22.26	1	30	60	60	480	
22-44	1,167,280	51.19	21.01	1	30	60	60	1,461	
45-64	356,631	51.66	23.61	1	30	60	60	660	
65-74	6,309	51.30	27.69	1	30	60	60	360	
75+	669	53.93	30.17	1	30	60	60	180	

Table 6a: Descriptive statistics of the length of all gaps between treatment episodes, in days ¹

Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
SpecGx Mixed Amphetamine Salt, 7 Day Gap	20,173	99.65	196.84	1	12	33	98	1,787
SpecGx Mixed Amphetamine Salt, 14 Day Gap	16,453	113.10	210.59	1	15	42	115	1,780
Aurolife Mixed Amphetamine Salt, 0 Day Gap	422,689	53.01	113.78	1	5	17	50	1,760
Aurolife Mixed Amphetamine Salt, 7 Day Gap	271,114	72.63	134.01	1	11	27	73	1,753
Aurolife Mixed Amphetamine Salt, 14 Day Gap	215,146	82.69	144.99	1	13	33	84	1,746
Any Mixed Amphetamine Salt, 0 Day Gap	623,250	65.24	135.48	1	7	22	61	2,182
Any Mixed Amphetamine Salt, 7 Day Gap	450,961	80.31	152.07	1	11	29	79	2,182
Any Mixed Amphetamine Salt, 14 Day Gap	359,295	91.24	164.07	1	13	34	92	2,182
Any Mixed Amphetamine Salt, 30 Day Gap	237,460	113.43	186.67	1	16	46	123	2,182
Any Mixed Amphetamine Salt, 45 Day Gap	171,755	134.42	204.68	1	21	59	153	2,182

¹For drugs with pre-specified allowable episode gap and extension, gaps observed between treatment episodes are estimated after dispensings within allowable episode gap are bridged and episode extension applied at the end of the last dispensing. If no episode gap or extension is specified, observed gaps between dispensings for drug of interest are reported

Table 6b: Descriptive statistics of the length of all gaps between treatment episodes, in days, by sex ¹								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
SpecGx Mixed Amphetamine Salt, 7 Day Gap	20,173	99.65	196.84	1	12	33	98	1,787
Female	10,471	102.14	204.56	1	12	33	97	1,787
Male	9,702	96.96	188.12	1	13	32	98	1,772
Other	0	-	-	-	-	-	-	-
SpecGx Mixed Amphetamine Salt, 14 Day Gap	16,453	113.10	210.59	1	15	42	115	1,780
Female	8,516	116.36	219.11	1	15	43	116	1,780
Male	7,937	109.61	201.00	1	15	41	113	1,765
Other	0	-	-	-	-	-	-	-
Aurolife Mixed Amphetamine Salt, 0 Day Gap	422,689	53.01	113.78	1	5	17	50	1,760
Female	229,300	53.30	114.40	1	5	17	50	1,760
Male	193,389	52.67	113.05	1	5	17	50	1,706
Other	0	-	-	-	-	-	-	-
Aurolife Mixed Amphetamine Salt, 7 Day Gap	271,114	72.63	134.01	1	11	27	73	1,753
Female	147,567	72.77	134.54	1	11	27	72	1,753
Male	123,547	72.47	133.38	1	11	27	74	1,699
Other	0	-	-	-	-	-	-	-
Aurolife Mixed Amphetamine Salt, 14 Day Gap	215,146	82.69	144.99	1	13	33	84	1,746
Female	116,978	82.93	145.66	1	13	33	84	1,746
Male	98,168	82.41	144.19	1	14	33	85	1,692
Other	0	-	-	-	-	-	-	-
Any Mixed Amphetamine Salt, 0 Day Gap	623,250	65.24	135.48	1	7	22	61	2,182
Female	325,777	64.78	134.70	1	7	22	60	2,182
Male	297,473	65.75	136.32	1	7	22	61	2,146
Other	0	-	-	-	-	-	-	-
Any Mixed Amphetamine Salt, 7 Day Gap	450,961	80.31	152.07	1	11	29	79	2,182
Female	236,184	79.39	150.94	1	11	29	77	2,182
Male	214,777	81.31	153.30	1	11	30	80	2,139
Other	0	-	-	-	-	-	-	-
Any Mixed Amphetamine Salt, 14 Day Gap	359,295	91.24	164.07	1	13	34	92	2,182
Female	187,647	90.19	162.86	1	13	34	90	2,182
Male	171,648	92.39	165.36	1	13	35	94	2,132
Other	0	-	-	-	-	-	-	-
Any Mixed Amphetamine Salt, 30 Day Gap	237,460	113.43	186.67	1	16	46	123	2,182
Female	122,978	112.56	185.74	1	16	45	121	2,182
Male	114,482	114.37	187.65	1	17	47	124	2,116
Other	0	-	-	-	-	-	-	-
Any Mixed Amphetamine Salt, 45 Day Gap	171,755	134.42	204.68	1	21	59	153	2,182
Female	88,117	134.07	203.94	1	21	58	152	2,182

¹For drugs with pre-specified allowable episode gap and extension, gaps observed between treatment episodes are estimated after dispensings within allowable episode gap are bridged and episode extension applied at the end of the last dispensing. If no episode gap or extension is specified, observed gaps between dispensings for drug of interest are reported



Table 6b: Descriptive statistics of the length of all gaps between treatment episodes, in days, by sex ¹								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Male	83,638	134.79	205.45	1	21	59	153	2,101
Other	0	-	-	-	-	-	-	-

¹For drugs with pre-specified allowable episode gap and extension, gaps observed between treatment episodes are estimated after dispensings within allowable episode gap are bridged and episode extension applied at the end of the last dispensing. If no episode gap or extension is specified, observed gaps between dispensings for drug of interest are reported

Table 6c: Descriptive statistics of the length of all gaps between treatment episodes, in days, by age group (years) ¹								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
SpecGx Mixed Amphetamine Salt, 7 Day Gap	20,173	99.65	196.84	1	12	33	98	1,787
00-01	0	-	-	-	-	-	-	-
02-04	6	27.17	26.66	9	11	18	27	80
05-09	299	72.72	139.46	1	9	26	82	1,759
10-14	865	80.56	149.09	1	11	28	80	1,376
15-18	1,068	84.75	170.27	1	11	30	82	1,740
19-21	1,365	118.61	228.05	1	12	36	112	1,574
22-44	11,365	98.90	194.66	1	13	33	97	1,787
45-64	5,076	104.77	208.02	1	13	34	102	1,785
65-74	121	84.43	157.27	1	12	39	90	1,320
75+	8	27.75	28.56	5	8	11	54	73
SpecGx Mixed Amphetamine Salt, 14 Day Gap	16,453	113.10	210.59	1	15	42	115	1,780
00-01	0	-	-	-	-	-	-	-
02-04	6	20.17	26.66	2	4	11	20	73
05-09	232	85.59	152.70	1	15	39	105	1,752
10-14	698	91.27	160.80	1	12	33	98	1,369
15-18	857	97.16	184.82	1	14	35	99	1,733
19-21	1,113	136.26	244.61	1	17	47	131	1,567
22-44	9,285	111.98	208.37	1	15	42	115	1,780
45-64	4,158	118.55	220.95	1	16	44	119	1,778
65-74	98	95.72	169.95	1	14	45	97	1,313
75+	6	28.00	29.83	1	1	20	61	66
Aurolife Mixed Amphetamine Salt, 0 Day Gap	422,689	53.01	113.78	1	5	17	50	1,760
00-01	2	109.50	7.78	104	104	110	115	115
02-04	294	33.70	78.23	1	4	11	30	823
05-09	10,239	53.03	118.84	1	5	18	48	1,604
10-14	16,550	59.15	124.25	1	6	20	57	1,566
15-18	20,487	66.31	128.73	1	7	24	67	1,706
19-21	35,019	62.17	126.51	1	5	20	61	1,519
22-44	250,388	50.72	109.68	1	4	16	47	1,760
45-64	88,142	51.66	113.07	1	5	16	47	1,643
65-74	1,416	55.80	120.55	1	5	17	49	1,362
75+	152	57.30	112.79	1	6	17	51	844
Aurolife Mixed Amphetamine Salt, 7 Day Gap	271,114	72.63	134.01	1	11	27	73	1,753
00-01	1	108.00	-	108	108	108	108	108
02-04	173	47.88	96.57	1	7	19	47	816
05-09	6,845	69.76	138.60	1	10	25	67	1,597
10-14	11,669	74.67	141.40	1	11	28	76	1,559

¹For drugs with pre-specified allowable episode gap and extension, gaps observed between treatment episodes are estimated after dispensings within allowable episode gap are bridged and episode extension applied at the end of the last dispensing. If no episode gap or extension is specified, observed gaps between dispensings for drug of interest are reported

Table 6c: Descriptive statistics of the length of all gaps between treatment episodes, in days, by age group (years) ¹								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
15-18	14,837	82.46	144.06	1	12	33	86	1,699
19-21	23,922	81.50	144.99	1	12	31	84	1,512
22-44	157,037	70.64	130.27	1	11	26	70	1,753
45-64	55,631	71.74	134.27	1	10	26	70	1,636
65-74	899	76.74	142.30	1	12	28	79	1,355
75+	100	76.59	130.81	1	9	33	74	837
Aurolife Mixed Amphetamine Salt, 14 Day Gap	215,146	82.69	144.99	1	13	33	84	1,746
00-01	1	101.00	-	101	101	101	101	101
02-04	123	58.30	109.86	1	11	21	56	809
05-09	5,345	80.35	151.40	1	12	29	79	1,590
10-14	9,342	84.67	152.74	1	13	33	87	1,552
15-18	12,246	91.67	153.46	1	15	40	97	1,692
19-21	19,347	92.28	155.44	1	15	38	97	1,505
22-44	124,341	80.31	141.06	1	13	32	82	1,746
45-64	43,611	82.57	146.01	1	14	32	83	1,629
65-74	715	86.76	152.06	1	14	32	84	1,348
75+	75	93.65	143.32	1	18	35	109	830
Any Mixed Amphetamine Salt, 0 Day Gap	623,250	65.24	135.48	1	7	22	61	2,182
00-01	3	14.00	11.53	1	1	18	23	23
02-04	625	86.96	195.12	1	6	17	58	1,577
05-09	28,228	72.59	165.33	1	6	20	60	1,917
10-14	50,141	78.57	159.90	1	9	27	73	2,146
15-18	62,770	81.71	154.48	1	10	30	82	2,046
19-21	74,111	72.65	137.72	1	9	27	75	2,112
22-44	293,770	59.76	126.15	1	6	20	54	2,053
45-64	111,233	57.52	123.33	1	6	20	53	2,182
65-74	2,136	63.37	131.82	1	7	24	60	1,403
75+	233	75.77	168.67	1	8	27	68	1,672
Any Mixed Amphetamine Salt, 7 Day Gap	450,961	80.31	152.07	1	11	29	79	2,182
00-01	1	11.00	-	11	11	11	11	11
02-04	443	114.31	223.06	1	7	24	92	1,570
05-09	19,980	92.98	189.10	1	11	28	81	1,910
10-14	38,542	92.95	175.73	1	12	33	90	2,139
15-18	49,572	94.24	166.83	1	14	37	98	2,039
19-21	56,282	86.20	151.06	1	12	34	92	2,105
22-44	206,420	74.83	143.08	1	10	27	72	2,046
45-64	77,985	72.03	140.44	1	10	27	69	2,182
65-74	1,562	76.98	148.21	1	11	30	76	1,396

¹For drugs with pre-specified allowable episode gap and extension, gaps observed between treatment episodes are estimated after dispensings within allowable episode gap are bridged and episode extension applied at the end of the last dispensing. If no episode gap or extension is specified, observed gaps between dispensings for drug of interest are reported

Table 6c: Descriptive statistics of the length of all gaps between treatment episodes, in days, by age group (years) ¹								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
75+	174	92.86	189.67	1	12	32	92	1,672
Any Mixed Amphetamine Salt, 14 Day Gap	359,295	91.24	164.07	1	13	34	92	2,182
00-01	1	4.00	-	4	4	4	4	4
02-04	328	146.10	248.09	1	12	39	148	1,563
05-09	15,929	107.44	205.34	1	12	34	98	1,903
10-14	31,746	104.11	188.05	1	14	39	103	2,132
15-18	41,554	103.50	176.31	1	15	42	109	2,032
19-21	46,125	96.19	161.02	1	15	40	105	1,914
22-44	161,452	85.78	155.33	1	12	32	86	2,039
45-64	60,782	82.41	152.32	1	12	31	81	2,182
65-74	1,242	86.15	157.27	1	14	35	85	1,389
75+	136	106.24	208.71	1	15	39	95	1,672
Any Mixed Amphetamine Salt, 30 Day Gap	237,460	113.43	186.67	1	16	46	123	2,182
00-01	0	-	-	-	-	-	-	-
02-04	216	195.56	278.94	1	23	70	275	1,547
05-09	10,589	138.50	236.04	1	16	49	141	1,887
10-14	21,855	127.64	210.68	1	18	51	133	2,116
15-18	29,573	122.82	195.04	1	19	53	137	2,016
19-21	32,253	114.86	178.62	1	18	52	128	1,914
22-44	103,250	108.40	178.44	1	15	43	117	2,023
45-64	38,822	103.25	175.93	1	14	41	109	2,182
65-74	813	106.20	182.63	1	17	44	104	1,373
75+	89	139.06	245.71	1	19	52	118	1,672
Any Mixed Amphetamine Salt, 45 Day Gap	171,755	134.42	204.68	1	21	59	153	2,182
00-01	0	-	-	-	-	-	-	-
02-04	175	225.65	292.96	2	23	105	335	1,532
05-09	7,795	167.81	259.51	1	22	64	189	1,872
10-14	16,466	148.82	228.51	1	23	62	166	2,101
15-18	22,625	139.83	209.48	1	23	63	162	2,001
19-21	24,331	130.89	191.94	1	23	62	150	1,914
22-44	73,036	129.94	196.82	1	20	56	149	2,008
45-64	26,668	126.18	196.51	1	19	54	141	2,182
65-74	591	125.13	203.55	1	19	50	129	1,358
75+	68	170.13	271.54	1	28	66	142	1,672

¹For drugs with pre-specified allowable episode gap and extension, gaps observed between treatment episodes are estimated after dispensings within allowable episode gap are bridged and episode extension applied at the end of the last dispensing. If no episode gap or extension is specified, observed gaps between dispensings for drug of interest are reported

Table 7: Counts of reason for censoring, all episodes and first episode								
	Total		Disenrollment		Evidence of death		Episode end	
	N	%	N	%	N	%	N	%
Episodes								
SpecGx Mixed Amphetamine Salt, 7 Day Gap	57,517	100.0	6,016	10.5	0	0.0	51,593	89.7
SpecGx Mixed Amphetamine Salt, 14 Day Gap	53,580	100.0	6,743	12.6	0	0.0	46,917	87.6
Aurolife Mixed Amphetamine Salt, 0 Day Gap	601,142	100.0	49,201	8.2	0	0.0	601,142	100.0
Aurolife Mixed Amphetamine Salt, 7 Day Gap	445,878	100.0	54,832	12.3	1	0.0	391,675	87.8
Aurolife Mixed Amphetamine Salt, 14 Day Gap	387,638	100.0	59,391	15.3	1	0.0	328,842	84.8
Any Mixed Amphetamine Salt, 0 Day Gap	1,036,740	100.0	219,575	21.2	17	0.0	1,036,725	100.0
Any Mixed Amphetamine Salt, 7 Day Gap	854,392	100.0	220,231	25.8	17	0.0	635,127	74.3
Any Mixed Amphetamine Salt, 14 Day Gap	754,666	100.0	220,948	29.3	17	0.0	534,574	70.8
Any Mixed Amphetamine Salt, 30 Day Gap	616,794	100.0	221,640	35.9	15	0.0	395,716	64.2
Any Mixed Amphetamine Salt, 45 Day Gap	538,239	100.0	220,709	41.0	15	0.0	318,093	59.1
Patients' First Episode								
SpecGx Mixed Amphetamine Salt, 7 Day Gap	37,344	100.0	3,629	9.7	0	0.0	33,774	90.4
SpecGx Mixed Amphetamine Salt, 14 Day Gap	37,127	100.0	4,336	11.7	0	0.0	32,843	88.5
Aurolife Mixed Amphetamine Salt, 0 Day Gap	178,453	100.0	13,197	7.4	0	0.0	178,453	100.0
Aurolife Mixed Amphetamine Salt, 7 Day Gap	174,764	100.0	19,528	11.2	1	0.0	155,480	89.0
Aurolife Mixed Amphetamine Salt, 14 Day Gap	172,492	100.0	24,039	13.9	1	0.0	148,714	86.2
Any Mixed Amphetamine Salt, 0 Day Gap	413,490	100.0	118,640	28.7	12	0.0	413,480	100.0
Any Mixed Amphetamine Salt, 7 Day Gap	403,431	100.0	130,487	32.3	12	0.0	273,374	67.8
Any Mixed Amphetamine Salt, 14 Day Gap	395,371	100.0	138,721	35.1	14	0.0	257,079	65.0
Any Mixed Amphetamine Salt, 30 Day Gap	379,334	100.0	152,816	40.3	14	0.0	226,860	59.8
Any Mixed Amphetamine Salt, 45 Day Gap	366,484	100.0	162,214	44.3	15	0.0	204,621	55.8

Table 8 : Cohort Attrition Table	
Attrition Criteria	Members
SpecGx Mixed Amphetamine Salt, 7 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	69,571 (0.1%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	69,571 (0.1%)
Exclusion - Members must have at least one episode defining index claim during the query period	69,571 (0.1%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	69,571 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	58,316 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	58,316 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	37,344 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	37,344 (0.0%)
SpecGx Mixed Amphetamine Salt, 14 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	69,571 (0.1%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	69,571 (0.1%)
Exclusion - Members must have at least one episode defining index claim during the query period	69,571 (0.1%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	69,571 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	58,101 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	58,101 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	37,127 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	37,127 (0.0%)
Aurolife Mixed Amphetamine Salt, 0 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)

Table 8: Cohort Attrition Table	
Attrition Criteria	Members
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	308,739 (0.3%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	308,739 (0.3%)
Exclusion - Members must have at least one episode defining index claim during the query period	308,739 (0.3%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	308,739 (0.3%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	263,454 (0.3%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	263,454 (0.3%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	178,453 (0.2%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	178,453 (0.2%)
Aurolife Mixed Amphetamine Salt, 7 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	308,739 (0.3%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	308,739 (0.3%)
Exclusion - Members must have at least one episode defining index claim during the query period	308,739 (0.3%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	308,739 (0.3%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	259,944 (0.3%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	259,944 (0.3%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	174,764 (0.2%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	174,764 (0.2%)
Aurolife Mixed Amphetamine Salt, 14 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	308,739 (0.3%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	308,739 (0.3%)
Exclusion - Members must have at least one episode defining index claim during the query period	308,739 (0.3%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	308,739 (0.3%)

Table 8 : Cohort Attrition Table	
Attrition Criteria	Members
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	257,853 (0.3%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	257,853 (0.3%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	172,492 (0.2%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	172,492 (0.2%)
Any Mixed Amphetamine Salt, 0 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	1,023,139 (1.1%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	1,023,139 (1.1%)
Exclusion - Members must have at least one episode defining index claim during the query period	944,857 (1.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	944,857 (1.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	628,775 (0.7%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	628,775 (0.7%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	413,490 (0.4%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	413,490 (0.4%)
Any Mixed Amphetamine Salt, 7 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	1,023,139 (1.1%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	1,023,139 (1.1%)
Exclusion - Members must have at least one episode defining index claim during the query period	943,075 (1.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	943,075 (1.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	617,953 (0.7%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	617,953 (0.7%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	403,431 (0.4%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	403,431 (0.4%)
Any Mixed Amphetamine Salt, 14 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)

Table 8 : Cohort Attrition Table	
Attrition Criteria	Members
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	1,023,139 (1.1%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	1,023,139 (1.1%)
Exclusion - Members must have at least one episode defining index claim during the query period	941,393 (1.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	941,393 (1.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	609,111 (0.7%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	609,111 (0.7%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	395,371 (0.4%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	395,371 (0.4%)
Any Mixed Amphetamine Salt, 30 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	1,023,139 (1.1%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	1,023,139 (1.1%)
Exclusion - Members must have at least one episode defining index claim during the query period	937,519 (1.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	937,519 (1.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	591,014 (0.6%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	591,014 (0.6%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	379,334 (0.4%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	379,334 (0.4%)
Any Mixed Amphetamine Salt, 45 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)

Table 8 : Cohort Attrition Table	
Attrition Criteria	Members
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	1,023,139 (1.1%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	1,023,139 (1.1%)
Exclusion - Members must have at least one episode defining index claim during the query period	933,865 (1.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	933,865 (1.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	576,111 (0.6%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	576,111 (0.6%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	366,484 (0.4%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	366,484 (0.4%)



Appendix A. Dates of Available Data for Each Data Partner (DP) up to Request End Date (03/31/2019) as of Query Distribution Date

Data Partner (Masked)	Start Date	End Date
DP01	01/01/2010	03/31/2019

Appendix B. Specifications Used to Define Parameters in this Query

Global Values

Enrollment Criteria: **Medical and Drug Coverage**

Enrollment Gap (Days): **45**

Age Groups (Years): **00-01, 02-04, 05-09, 10-14, 15-18, 19-21, 22-44, 45-64, 65-74, 75+**

Query Period: **01/01/2013-03/31/2019**

Baseline Characteristics Table: **Yes**

Baseline Evaluation Window (Day): **-183,0**

#	Cohort Name	Index Exposure	Pre-Index Enrollment Period (Days)	Washout Period (Days)	Treatment Episode Gap (Days)	Treatment Episode Extension (Days)	Inclusion/Exclusion	Criteria	Criteria Definition	Evaluation Period Start (Day)	Evaluation Period End (Day)
1	SpecGx Mixed Amphetamine Salt, 7 Day Gap	MAS IR SpecGx ^[1]	183	0	7	7	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[2]	-183	0
							--	--	--	--	--
2	SpecGx Mixed Amphetamine Salt, 14 Day Gap	MAS IR SpecGx ^[3]	183	0	14	14	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[4]	-183	0
							--	--	--	--	--
3	Aurolife Mixed Amphetamine Salt, 0 Day Gap	MAS IR Aurolife ^[5]	183	0	0	0	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[6]	-183	0
							--	--	--	--	--
4	Aurolife Mixed Amphetamine Salt, 7 Day Gap	MAS IR Aurolife ^[7]	183	0	7	7	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[8]	-183	0
							--	--	--	--	--
5	Aurolife Mixed Amphetamine Salt, 14 Day Gap	MAS IR Aurolife ^[9]	183	0	14	14	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[10]	-183	0
							--	--	--	--	--
6	Any Mixed Amphetamine Salt, 0 Day Gap	Any MAS IR ^[11]	183	0	0	0	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[12]	-183	0
							--	--	--	--	--
7	Any Mixed Amphetamine Salt, 7 Day Gap	Any MAS IR ^[13]	183	0	7	7	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[14]	-183	0
							--	--	--	--	--
8	Any Mixed Amphetamine Salt, 14 Day Gap	Any MAS IR ^[15]	183	0	14	14	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[16]	-183	0
							--	--	--	--	--
9	Any Mixed Amphetamine Salt, 30 Day Gap	Any MAS IR ^[17]	183	0	30	30	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[18]	-183	0
							--	--	--	--	--
10	Any Mixed Amphetamine Salt, 45 Day Gap	Any MAS IR ^[19]	183	0	45	45	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[20]	-183	0
							--	--	--	--	--

ICD-9, ICD-10, HCPCS AND CPT are provided by Optum360
NDCs are checked against First Data Bank's MedKnowledge.

Appendix of Generic Names and Chronic Conditions

- [1] See Appendix C for index exposure definitions.
- [2] See Appendix D for inclusion criteria definitions.
- [3] See Appendix C for index exposure definitions.
- [4] See Appendix D for inclusion criteria definitions.
- [5] See Appendix C for index exposure definitions.
- [6] See Appendix D for inclusion criteria definitions.
- [7] See Appendix C for index exposure definitions.
- [8] See Appendix D for inclusion criteria definitions.
- [9] See Appendix C for index exposure definitions.
- [10] See Appendix D for inclusion criteria definitions.
- [11] See Appendix C for index exposure definitions.
- [12] See Appendix D for inclusion criteria definitions.
- [13] See Appendix C for index exposure definitions.
- [14] See Appendix D for inclusion criteria definitions.
- [15] See Appendix C for index exposure definitions.
- [16] See Appendix D for inclusion criteria definitions.
- [17] See Appendix C for index exposure definitions.
- [18] See Appendix D for inclusion criteria definitions.
- [19] See Appendix C for index exposure definitions.
- [20] See Appendix D for inclusion criteria definitions.

Baseline Characteristics Table

Acquired Hypothyroidism	Chronic Kidney Disease	Hypertension
Acute Myocardial Infarction	Chronic Obstructive Pulmonary Disease	Ischemic Heart Disease
Alzheimer's Disease	Colorectal Cancer	Lung Cancer
Alzheimer's Disease, Related Disorders, or Senile Dementia	Depression	Osteoporosis
Anemia	Diabetes	Prostate Cancer
Asthma	Endometrial Cancer	Rheumatoid Arthritis / Osteoarthritis
Atrial Fibrillation	Glaucoma	Stroke / Transient Ischemic Attack
Benign Prostatic Hyperplasia	Heart Failure	
Breast Cancer	Hip / Pelvic Fracture	
Cataracts	Hyperlipidemia	

Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module

Age Groups - Age groups of members included in the cohort. Strata also used for reporting purposes.

Ambulatory Visit (AV) - A care setting value including visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Baseline Characteristics Table - Optional table containing general characteristics of study population, including background rates of 27 chronic conditions from the CMS Chronic Condition Warehouse (see above if table requested). Users define an evaluation period for the presence of baseline characteristics.

Care Setting - Type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Charlson/Elixhauser Combined Comorbidity Score - Calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Cohort Definition - Cohort includes all valid exposure episodes during the query period. Only the first valid episode's incidence is assessed using the washout period.

Emergency Department (ED) - A care setting value including ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Enrollment Criteria - Type of coverage required during enrollment period. By default, all patients must have medical and drug coverage.

Enrollment Gap - Allowed gap between coverage periods.

Episodes - Treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Inclusion/Exclusion - Contains the comprehensive set of codes used to define additional cohort inclusion and/or exclusion criteria (e.g., restrict cohort to individuals with evidence of a pre-existing condition 183 days before the index date). Criteria could be defined with complex algorithms (e.g., diagnosis codes and drug codes) defined under Criteria Definition.

Inpatient Hospital Stay (IP) - A care setting value including all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - A care setting value including hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - A care setting value including other non-overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - Diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the CareSetting/PDX parameter.

Query Period - The period of time which patients can contribute index-defining exposure/events. Data prior to the start date may be used to determine enrollment, washout, and other cohort inclusion criteria.

Treatment Episode Extension - The episode extension adds the selected number of days to the end of an episode to count as exposed time.

Treatment Episode Gap - The period before an exposure episode during which an individual cannot have evidence of incidence-defining criteria.

Washout Period - The period before an exposure episode during which an individual cannot have evidence of incidence-defining criteria.

Appendix C. List of National Drug Codes (NDCs) and Generic Names of Medical Products Used to Define Index Exposure in this Request

NDC	Generic Name	Manufacturer
SpecGx Mixed Amphetamine Salt Immediate Release		
00406888401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
00406888501	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
00406889101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
00406889201	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
00406889301	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
00406889401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
Aurolife Mixed Amphetamine Salt Immediate Release		
13107006801	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007001	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007201	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007301	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107006805	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107006825	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107006850	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107006899	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107006901	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107006905	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107006925	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107006950	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107006999	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007005	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007025	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007050	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007099	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007105	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007125	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007150	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007199	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007205	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007225	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007250	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007299	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007305	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007325	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007350	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	

Appendix C. List of National Drug Codes (NDCs) and Generic Names of Medical Products Used to Define Index Exposure in this Request

NDC	Generic Name	Manufacturer
13107007399	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007405	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007425	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007450	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
13107007499	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
Any Mixed Amphetamine Salt Immediate Release		
00406888401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mallinckrodt
00406888501	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mallinckrodt
00406889101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mallinckrodt
00406889201	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mallinckrodt
00406889301	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mallinckrodt
00406889401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mallinckrodt
13107006801	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007001	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007201	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007301	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107006805	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107006825	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107006850	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107006899	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107006901	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107006905	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107006925	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107006950	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107006999	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007005	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007025	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007050	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007099	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007105	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007125	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007150	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007199	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007205	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007225	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007250	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC

Appendix C. List of National Drug Codes (NDCs) and Generic Names of Medical Products Used to Define Index Exposure in this Request

NDC	Generic Name	Manufacturer
13107007299	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007305	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007325	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007350	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007399	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007405	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007425	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007450	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
13107007499	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
00185008401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sandoz
00185011101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sandoz
00185040101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sandoz
00185040401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sandoz
00185083101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sandoz
00185084201	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sandoz
00185085301	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sandoz
00185086401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sandoz
16714080201	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
16714080301	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
16714080401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
16714080501	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
16714080601	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
16714080701	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
16714080801	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
16714094801	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
16714094901	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
16714095001	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
16714095101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
16714095201	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
16714095301	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
16714095401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
00555076202	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Barr
00555076302	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Barr
00555076602	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Barr
004068884	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mallinckrodt
004068885	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mallinckrodt
004068891	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mallinckrodt
004068892	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mallinckrodt
004068893	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mallinckrodt

Appendix C. List of National Drug Codes (NDCs) and Generic Names of Medical Products Used to Define Index Exposure in this Request

NDC	Generic Name	Manufacturer
004068894	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mallinckrodt
00115148601	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Amneal Pharmaceuticals LLC
00115148701	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Amneal Pharmaceuticals LLC
00115148801	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Amneal Pharmaceuticals LLC
00115148901	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Amneal Pharmaceuticals LLC
00115149001	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Amneal Pharmaceuticals LLC
00115149101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Amneal Pharmaceuticals LLC
00378454101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mylan
00378454201	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mylan
00378454301	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mylan
00378454401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mylan
00378454501	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mylan
00378454601	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mylan
00378454701	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mylan
00527150137	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
00527150037	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
00527150337	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
00527150637	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
00527150437	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
00527150237	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
00527150537	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
00555077502	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
00555077602	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
00555077702	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
00555097102	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
00555097202	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
00555097302	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
00555097402	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
11534019001	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sunrise Pharmaceutical
11534019401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sunrise Pharmaceutical
11534019201	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sunrise Pharmaceutical
11534019501	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sunrise Pharmaceutical
11534019601	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sunrise Pharmaceutical
11534019101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sunrise Pharmaceutical
11534019301	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sunrise Pharmaceutical
42806034401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Epic Pharma LLC
42806033901	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Epic Pharma LLC
42806034501	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Epic Pharma LLC
42806034301	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Epic Pharma LLC

Appendix C. List of National Drug Codes (NDCs) and Generic Names of Medical Products Used to Define Index Exposure in this Request

NDC	Generic Name	Manufacturer
42806034101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Epic Pharma LLC
47781017601	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Alvogen Inc
47781017901	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Alvogen Inc
47781018001	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Alvogen Inc
52343016601	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Acetris Health
52343016001	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Acetris Health
52343016201	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Acetris Health
52343016401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Acetris Health
52343016501	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Acetris Health
52343016301	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Acetris Health
52343016101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Acetris Health
57664064208	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sun Pharmaceuticals
57664064108	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sun Pharmaceuticals
57664064408	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sun Pharmaceuticals
57664064508	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sun Pharmaceuticals
57664064708	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sun Pharmaceuticals
57664064308	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sun Pharmaceuticals
57664064608	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sun Pharmaceuticals
63629373001	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
68382095101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Zydus Pharmaceuticals
68382095401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Zydus Pharmaceuticals
68382095501	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Zydus Pharmaceuticals
68382095001	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Zydus Pharmaceuticals
68382095201	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Zydus Pharmaceuticals
68382095301	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Zydus Pharmaceuticals
68382095601	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Zydus Pharmaceuticals
00527150241	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
00527150041	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
00527150541	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
00527150441	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
00527150141	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
00527150341	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
00527150641	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
11534019603	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sunrise Pharmaceutical
11534019103	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sunrise Pharmaceutical
11534019203	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sunrise Pharmaceutical
11534019403	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sunrise Pharmaceutical
11534019003	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sunrise Pharmaceutical
11534019303	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sunrise Pharmaceutical

Appendix C. List of National Drug Codes (NDCs) and Generic Names of Medical Products Used to Define Index Exposure in this Request

NDC	Generic Name	Manufacturer
11534019503	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sunrise Pharmaceutical
71335062701	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
71335062702	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
71335062703	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
71335062704	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
71335062705	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
71335069901	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
71335069902	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
71335069903	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
71335069904	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
71335069905	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
71335108101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
71335108102	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
71335108103	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
71335124901	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
71335124902	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
71335124903	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
71335124904	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
71335124905	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
63629373002	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
63629373003	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
63629373004	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
63629373005	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
63629748701	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
63629748702	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
63629748703	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	
001850084	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sandoz
001850111	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sandoz
001850401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sandoz
001850404	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sandoz
001850831	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sandoz
001850842	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sandoz
001850853	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sandoz
001850864	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sandoz
002283046	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Actavis/Teva
002283047	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Actavis/Teva
002283048	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Actavis/Teva
002283049	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Actavis/Teva
002283050	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Actavis/Teva

Appendix C. List of National Drug Codes (NDCs) and Generic Names of Medical Products Used to Define Index Exposure in this Request

NDC	Generic Name	Manufacturer
002283051	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Actavis/Teva
002283052	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Actavis/Teva
003784541	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mylan
003784542	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mylan
003784543	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mylan
003784544	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mylan
003784545	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mylan
003784546	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mylan
003784547	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mylan
005271500	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
005271501	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
005271502	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
005271503	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
005271504	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
005271505	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
005271506	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Lannett Co. Inc
005550762	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Barr
005550763	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Barr
005550764	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
005550765	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
005550766	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Barr
005550767	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
005550768	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
005550775	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
005550776	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
005550777	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
005550971	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
005550972	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
005550973	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
005550974	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
131070068	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
131070070	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
131070072	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
131070073	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
131070074	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Aurolife Pharma, LLC
165900738	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Stat Rx USA
165900739	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Stat Rx USA
167140802	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC

Appendix C. List of National Drug Codes (NDCs) and Generic Names of Medical Products Used to Define Index Exposure in this Request

NDC	Generic Name	Manufacturer
167140803	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
167140804	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
167140805	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
167140806	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
167140807	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
167140808	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
167140948	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
167140949	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
167140950	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
167140951	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
167140952	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
167140953	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
167140954	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	NorthstarRx LLC
234907973	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Palmetto State
234907974	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Palmetto State
234907975	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Palmetto State
353560631	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Quality Care
428060339	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Epic Pharma LLC
428060341	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Epic Pharma LLC
428060343	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Epic Pharma LLC
428060344	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Epic Pharma LLC
428060345	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Epic Pharma LLC
459630743	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Actavis Pharma
459630745	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Actavis Pharma
459630748	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Actavis Pharma
459630749	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Actavis Pharma
477810176	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Alvogen Inc
477810179	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Alvogen Inc
477810180	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Alvogen Inc
523430160	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Acetris Health
523430161	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Acetris Health
523430162	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Acetris Health
523430163	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Acetris Health
523430164	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Acetris Health
523430165	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Acetris Health
523430166	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Acetris Health
548684631	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Physicians TC.
548684728	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Physicians TC.
548684863	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Physicians TC.

Appendix C. List of National Drug Codes (NDCs) and Generic Names of Medical Products Used to Define Index Exposure in this Request

NDC	Generic Name	Manufacturer
548685103	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Physicians TC.
548685387	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Physicians TC.
552890680	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	PD-RX Pharm
552890700	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	PD-RX Pharm
552890722	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	PD-RX Pharm
576640641	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sun Pharmaceuticals
576640642	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sun Pharmaceuticals
576640643	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sun Pharmaceuticals
576640644	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sun Pharmaceuticals
576640645	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sun Pharmaceuticals
576640646	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sun Pharmaceuticals
576640647	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Sun Pharmaceuticals
578440105	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
578440110	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
578440112	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
578440115	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
578440117	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
578440120	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
578440130	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Teva USA
606870133	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	AHP
606870154	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	AHP
636293730	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
636293768	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
636293769	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Bryant Ranch PR
647200130	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	CorePharma LLC
647200131	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	CorePharma LLC
647200132	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	CorePharma LLC
647200133	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	CorePharma LLC
647200134	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	CorePharma LLC
647200135	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	CorePharma LLC
647200136	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	CorePharma LLC
680840874	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	AHP
680840936	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	AHP
680840943	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	AHP
683820950	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Zydus Pharmaceuticals
683820951	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Zydus Pharmaceuticals
683820952	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Zydus Pharmaceuticals
683820953	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Zydus Pharmaceuticals
683820954	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Zydus Pharmaceuticals

Appendix C. List of National Drug Codes (NDCs) and Generic Names of Medical Products Used to Define Index Exposure in this Request

NDC	Generic Name	Manufacturer
683820955	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Zydus Pharmaceuticals
683820956	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Zydus Pharmaceuticals

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Inclusion Criteria in this Request

Code	Code Category	Code Type	Description
Narcolepsy/Attention Deficit Hyperactivity Disorder (ADHD)			
31200	Diagnosis	ICD-9-CM	Undersocialized conduct disorder, aggressive type, unspecified
31201	Diagnosis	ICD-9-CM	Undersocialized conduct disorder, aggressive type, mild
31202	Diagnosis	ICD-9-CM	Undersocialized conduct disorder, aggressive type, moderate
31203	Diagnosis	ICD-9-CM	Undersocialized conduct disorder, aggressive type, severe
31210	Diagnosis	ICD-9-CM	Undersocialized conduct disorder, unaggressive type, unspecified
31211	Diagnosis	ICD-9-CM	Undersocialized conduct disorder, unaggressive type, mild
31212	Diagnosis	ICD-9-CM	Undersocialized conduct disorder, unaggressive type, moderate
31213	Diagnosis	ICD-9-CM	Undersocialized conduct disorder, unaggressive type, severe
31220	Diagnosis	ICD-9-CM	Socialized conduct disorder, unspecified
31221	Diagnosis	ICD-9-CM	Socialized conduct disorder, mild
31222	Diagnosis	ICD-9-CM	Socialized conduct disorder, moderate
31223	Diagnosis	ICD-9-CM	Socialized conduct disorder, severe
31230	Diagnosis	ICD-9-CM	Impulse control disorder, unspecified
31231	Diagnosis	ICD-9-CM	Pathological gambling
31232	Diagnosis	ICD-9-CM	Kleptomania
31233	Diagnosis	ICD-9-CM	Pyromania
31234	Diagnosis	ICD-9-CM	Intermittent explosive disorder
31235	Diagnosis	ICD-9-CM	Isolated explosive disorder
31239	Diagnosis	ICD-9-CM	Other disorder of impulse control
3124	Diagnosis	ICD-9-CM	Mixed disturbance of conduct and emotions
31281	Diagnosis	ICD-9-CM	Conduct disorder, childhood onset type
31282	Diagnosis	ICD-9-CM	Conduct disorder, adolescent onset type
31289	Diagnosis	ICD-9-CM	Other specified disturbance of conduct, not elsewhere classified
3129	Diagnosis	ICD-9-CM	Unspecified disturbance of conduct
31400	Diagnosis	ICD-9-CM	Attention deficit disorder of childhood without mention of hyperactivity
31401	Diagnosis	ICD-9-CM	Attention deficit disorder of childhood with hyperactivity
3141	Diagnosis	ICD-9-CM	Hyperkinesis of childhood with developmental delay
3142	Diagnosis	ICD-9-CM	Hyperkinetic conduct disorder of childhood
3148	Diagnosis	ICD-9-CM	Other specified manifestations of hyperkinetic syndrome of childhood
3149	Diagnosis	ICD-9-CM	Unspecified hyperkinetic syndrome of childhood
F630	Diagnosis	ICD-10-CM	Pathological gambling
F631	Diagnosis	ICD-10-CM	Pyromania
F632	Diagnosis	ICD-10-CM	Kleptomania
F633	Diagnosis	ICD-10-CM	Trichotillomania
F6381	Diagnosis	ICD-10-CM	Intermittent explosive disorder
F6389	Diagnosis	ICD-10-CM	Other impulse disorders
F639	Diagnosis	ICD-10-CM	Impulse disorder, unspecified
F900	Diagnosis	ICD-10-CM	Attention-deficit hyperactivity disorder, predominantly inattentive type
F901	Diagnosis	ICD-10-CM	Attention-deficit hyperactivity disorder, predominantly hyperactive type

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Inclusion Criteria in this Request

Code	Code Category	Code Type	Description
F902	Diagnosis	ICD-10-CM	Attention-deficit hyperactivity disorder, combined type
F908	Diagnosis	ICD-10-CM	Attention-deficit hyperactivity disorder, other type
F909	Diagnosis	ICD-10-CM	Attention-deficit hyperactivity disorder, unspecified type
F910	Diagnosis	ICD-10-CM	Conduct disorder confined to family context
F911	Diagnosis	ICD-10-CM	Conduct disorder, childhood-onset type
F912	Diagnosis	ICD-10-CM	Conduct disorder, adolescent-onset type
F913	Diagnosis	ICD-10-CM	Oppositional defiant disorder
F918	Diagnosis	ICD-10-CM	Other conduct disorders
F919	Diagnosis	ICD-10-CM	Conduct disorder, unspecified
347	Diagnosis	ICD-9-CM	Cataplexy and narcolepsy
3470	Diagnosis	ICD-9-CM	Narcolepsy
34700	Diagnosis	ICD-9-CM	Narcolepsy, without cataplexy
34701	Diagnosis	ICD-9-CM	Narcolepsy, with cataplexy
3471	Diagnosis	ICD-9-CM	Narcolepsy in conditions classified elsewhere
34710	Diagnosis	ICD-9-CM	Narcolepsy in conditions classified elsewhere, without cataplexy
34711	Diagnosis	ICD-9-CM	Narcolepsy in conditions classified elsewhere, with cataplexy
G474	Diagnosis	ICD-10-CM	Narcolepsy and cataplexy
G4741	Diagnosis	ICD-10-CM	Narcolepsy
G47411	Diagnosis	ICD-10-CM	Narcolepsy with cataplexy
G47419	Diagnosis	ICD-10-CM	Narcolepsy without cataplexy
G4742	Diagnosis	ICD-10-CM	Narcolepsy in conditions classified elsewhere
G47421	Diagnosis	ICD-10-CM	Narcolepsy in conditions classified elsewhere with cataplexy
G47429	Diagnosis	ICD-10-CM	Narcolepsy in conditions classified elsewhere without cataplexy